Clinical Development
AMN107 (NILOTINIB ) 
TASIGNA
Oncology Clinical Protocol CAMN107A2409 / [STUDY_ID_REMOVED]
An open label, multi -center nilotinib roll -over protocol for 
patients w ho hav e completed a previous Nov artis -
sponsored nilotinib study and are judged by [CONTACT_5334] 2012 -003902 -28
Version number 05 (Clean )
Development phase IV
Document status Final
Release date 30-Aug-2018
Property of [COMPANY_001]
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of [COMPANY_001]
Template version 19-Nov-2015

[COMPANY_001] Confidential Page 2
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Table of contents
Table of contents ................................................................................................................. [ADDRESS_4784] of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Amendment 05 (30
-Aug-2018) ......................................................................................... 10
Amendment 04 (27
-Jul-2016) ........................................................................................... 12
Summary  of previous amendments ................................................................................... 13
Protocol Summary ............................................................................................................. 20
1Background ........................................................................................................................ 22
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_5303] .............. 22
1.1.1 Overview of chronic myeloid leukemia (CML) .................................... 22
1.1.2 Overview of gastrointestinal stromal tumors (GI ST)............................ 22
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 23
1.2.1 Overview of nilotinib ............................................................................ 23
2Rationale ................................ ................................ ................................ ............................ 27
2.1 Study  rationale and purpose ................................................................................... 27
2.2 Rationale for the stud y design ............................................................................... 27
2.3 Rationale for dose and regimen selection .............................................................. 27
2.4
Rationale for choice of combination drugs............................................................ 27
2.5 Rationale for choice of com parators drugs ............................................................ 27
2.6 Risks and benefits .................................................................................................. 27
3Objectives and endpoints
................................................................................................... 28
4Study  design ................................ ................................ ................................ ...................... 30
4.1 Description of stud y design ................................................................................... 30
4.2 Timing of interim anal yses and design adaptations ............................................... 31
4.3
Definition of end of study ...................................................................................... 31
4.4 Early study termination .......................................................................................... 31
5Population ................................ ................................ ................................ .......................... 31
5.1 Patient population .................................................................................................. 31
5.2 Inclusion criteria .................................................................................................... 31
5.3 Exclusion criteria ................................................................................................... 32
6Treatment ................................ ................................ ................................ ........................... 33
6.1 Study  treatment ...................................................................................................... 33
6.1.1 Dosing regimen ..................................................................................... 33

[COMPANY_001] Confidential Page 3
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
6.1.2 Ancillary  treatments .............................................................................. 34
6.1.3
Rescue medication ................................................................................ 34
6.1.4 Guidelines for continuation of treatment .............................................. 34
6.1.5 Treatment duration ................................................................................ 34
6.2 Dose escalation guidelines ..................................................................................... 34
6.2.1 Starting dose rationale ........................................................................... 34
6.3 Dose modifications ................................................................................................ 34
6.3.1 Dose modification and dose delay ........................................................ 34
6.3.2 Dose reduction guidelines for study  drug -related toxicity  for 
pediatric patients ................................................................................... 40
6.3.3 Management of cholesterol increases ................................................... 47
6.3.4 Management of glucose increases ......................................................... 47
6.3.5 Management of other cardiac risk factors ............................................. 47
6.3.6 Management of ischemic vascular or cardiovascular events ................ 47
6.3.7 Hepatitis B reactivation ......................................................................... 48
6.3.8 Follow up on potential drug -induced liver injury  (DILI) cases ............ 48
6.4
Concomitant medications ...................................................................................... 49
6.4.1 Prohibited concomitant therap y
............................................................ 49
6.4.2 Use of Bisphosphonates (or other concomitant agents) ........................ 50
6.5 Patient numbering, treatment assignment or randomization ................................. 50
6.5.1
Patient numbering ................................................................................. 50
6.5.2
Treatment assignment or randomization............................................... 51
6.5.3 Treatment blinding ................................................................................ 51
6.6 Study  drug preparation and dispensation ............................................................... 51
6.6.1 Study  treatment packaging and labeling ............................................... 51
6.6.2 Drug supply  and storage ........................................................................ 52
6.6.3 Study drug compliance and accountabilit y
........................................... 52
6.6.4 Disposal and destruction ....................................................................... 52
7
Visit schedule and assessments ......................................................................................... 53
7.1 Study  flow and visit schedule ................................................................................ 53
7.1.1 Molecular pre -screening ........................................................................ 55
7.1.2 Screening ............................................................................................... 55
7.1.3 Treatment period ................................................................................... 55
7.1.4 Pregnancy  and assessment of fertility ................................................... 55
7.1.5 Discontinuation of study treatment ....................................................... 56
7.1.6 Withdrawal of consent .......................................................................... 57

[COMPANY_001] Confidential Page 4
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
7.1.[ADDRESS_4785]
......................................................... 61
8.2 Serious adverse events ........................................................................................... 62
8.2.1
Definitions............................................................................................. 62
8.2.2
Reporting............................................................................................... 62
8.3 Emergency  unblinding of treatment assignment ................................................... 63
8.4 Pregnancies ............................................................................................................ 63
8.5 Warnings and precautions ...................................................................................... 64
8.6 Data Monitoring Committee .................................................................................. 64
8.7 Steering Committee ............................................................................................... 64
9Data collection and management ................................ ................................ ....................... 64
9.1 Data confidentiality ............................................................................................... 64
9.2 Site monitoring ...................................................................................................... 64
9.3
Data collection....................................................................................................... 65
9.4 Database management and quality  control ............................................................ 65
10Statistical methods and data anal ysis................................................................................ 66
10.1 Analy sis sets .......................................................................................................... 66
10.1.1 Full Anal ysis Set ................................................................................... 66
10.1.2 Safety  Set
.............................................................................................. 66
10.1.3 Dose -
determining anal ysis set............................................................... 66
10.2 Patient demographics/other baseline characteristics ............................................. 66
10.3 Treatments (stud y treatment, com pliance) ................................ ............................ 66
10.4 Primary  objective ................................................................................................... 66
10.4.1 Variable ................................................................................................. 66
10.4.2 Statistical hy pothesis, model, and method of analy sis.......................... 66

[COMPANY_001] Confidential Page 5
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
10.4.3 Handling of missing values/censoring/discontinuations ....................... 66
10.4.4 Supportive analy ses............................................................................... 66
10.5 Secondary  objectives ............................................................................................. 67
10.5.1 Key secondary  objective(s) ................................................................... 67
10.5.2 Other secondary  efficacy objectives ..................................................... 67
10.5.3 Safety  objectives ................................................................................... 68
10.6 Interim anal ysis...................................................................................................... 68
10.7
Sample size calculation.......................................................................................... 68
10.8 Power for anal ysis of key secondary  variables
...................................................... 68
11Ethical considerations and administrative procedures ...................................................... 69
11.1 Regulatory  and ethical compliance ........................................................................ 69
11.2 Responsibilities of the investigator and IRB/ IEC/REB ......................................... [ADDRESS_4786] keepi[INVESTIGATOR_5304]
....................... 70
11.7 Confidentiality  of study  documents and patient records ....................................... 71
11.8
Audits and inspections........................................................................................... 71
11.9 Financial disclosures .............................................................................................. 71
12Protocol adherence ............................................................................................................ 71
12.1 Amendments to the protocol .................................................................................. 71
13References (available upon request) .................................................................................. 72
14Appendices ........................................................................................................................ 74
14.1 Appendix I : Guidance on concomitant medications with CYP3A and QTc 
prolongation potential interactions ........................................................................ 74

[COMPANY_001] Confidential Page 6
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
List of figures
Figure [ADDRESS_4787] of tables
Table 3
-1 Objectives and related endpoints .......................................................... 29
Table 6
-1 Dose and treatment schedule................................................................. 33
Table 6
-2 Summary  of nilotinib dose reduction guidelines for study  drug -
related non- hematologic toxicity  and for ischemic vascular and 
cardiovascular events regardless of stud y drug relationship (adult 
patients)................................................................................................. 36
Table 6
-3 Summary  of dose reduction guidelines for study  drug -related 
hematological toxicity ........................................................................... 40
Table 6
-4 Recommended criteria for interruption and re -initiation of nilotinib 
for drug -related toxicities and for ischemic vascular and 
cardiovascular events regardless of study drug relationship ................. 41
Table 6-5 Preparation and dispensing ................................................................... 51
Table 6
-6 Packaging and labeling ......................................................................... 52
Table 6
-7 Supply  and storage of study  treatments ................................................ 52
Table 7
-1 Visit evaluation schedule ...................................................................... 54
Table 14
-1 Medications that can induce CYP3A4 .................................................. 74
Table 14
-2 Medications that can inhibit CYP3A4 .................................................. 75
Table 14
-3 CYP3A4 substrates: Narrow therapeutic index, sensitive, and 
others. .................................................................................................... 76

[COMPANY_001] Confidential Page 7
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
List of abbreviations
AE Adverse event
AMN107 Nilotinib /Tasigna
AP Accelerated phase (of CML)
AUC Area under the plasma concentration -time curve
AUC (0 -∞) Area under the plasma concentration -time curve extrapolated to infinity
BC Blast crisis (of CML)
BCRP Breast cancer resistance protein
BID bis in diem, twice daily
CCyR complete cytogenetic response
CHR Complete hematological response
Cmax The maximum (peak) observed plasma drug concentration after oral dose administration 
(mass X volume -1)
CML Chronic myeloid /myelogenous leukemia
CMR Complete molecular response
CP Chronic phase (of CML)
CRF Case report/record form
CRO Contract research organization
CSR Clinical Study Report
CYP3A4 Cytochrome 3A4
DDI Drug –drug interactions
EC European Commission
ECG Electrocardiogram
eCRF Electronic Case report/record form
EDC Electronic data capture
EMA European Medicines Agency
EoT End of treatment
FDA Food and Drug Administration
GCP Good Clinical Practice
GI Gastrointestinal
GIST Gastrointestinal stromal tumors
h Hour
H2 Histamine receptor 
HBc Ab Hepatitis B Core Antibody
HBs Ag Hepatitis B Surface Antigen
HGC hard gelatin capsules
HMG-CoA Hydroxy -Methyl -Glutaryl -Coenzyme A
IB Investigator brochure
ICH International Conference on Harmonization
ICVE Ischemic Cerebrovascular Events
IEC Independent Ethics Committee
IHD Ischemic Heart Disease
IIT Investigator initiated trial
IN Investigator Notification
IRB Institutional Review Board
IUD Intrauterine device
IUS Intrauterine system

[COMPANY_001] Confidential Page 8
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
MCyR Major cytogenetic response
MRP2 Multi -resistance protein 2
o.d. Omnia die /once a day
OC Oral contraceptive
OCRDC Oracle Clinical Remote Data Capture
OGD&GMA Oncology Global Development & Global Medical Affairs
OS Overall survival
p.o. Per os /by [CONTACT_1966]/orally
PAOD Peripheral Artery Occlusive Disease 
PDGRD- α Platelet -derived growth factor receptors α
PFS Progression -free survival
P-gp P-glycoprotein
Ph Philadelphia (chromosome)
PHI Protected Health Information
PK Pharmacokinetics
q.d. quaque die / once daily
QT Q to T interval (ECG)
SAE Serious adverse event
SCT Stem cell transplantation
SmPC Summary of Product Characteristics
SOC system organ class
T1/2 The elimination half-life associated with the terminal slope of a semi logarithmic 
concentration -tine curve (time)
TKI Tyrosine kinase inhibitors
Tmax The time to reach maximum (Cmax) plasma drug concentration after oral dose 
administration (time)
US PI [INVESTIGATOR_5305] 9
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Glossary  of terms
Dose level The dose of drug given to the patient (total daily dose).
Enrollment Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol).
Investigational treatment Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). This 
also includes approved drugs used outside of t heir indication/approved 
dosage, or that are tested in a fixed combination. Investigational treatment 
generally does not include other study treatments administered as 
concomitant background therapy required or allowed by [CONTACT_5335]/dosage.
Medication number A unique identifier on the label of each study treatment package which is 
linked to one of the treatment groups of a study.
Other study treatment Any drug administered to the patient as part of the required study 
procedures that were not included in the investigational treatment.
Parent study The original [COMPANY_001] -sponsored, Oncology Clinical Development & Medical 
Affairs study where the patient was first enrolled and received nilotinib 
treatment.
Patient number A unique identifying number assigned to each patient who enrolls in the 
study.
Personal Data Subject information collected by [CONTACT_5336]. This data includes subject 
identifier information, study information and biological samples.
Roll-over study A roll -over study allows patients from multiple parent studies spanning 
multiple indications to continue to be treated within one study after the 
completion of the parent study/ies
Study treatment Includes any drug or combination of drugs in any study arm administered to 
the patient as part of the required study procedures, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational trea tment 
component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non -investigational 
treatments in combination.
Withdrawal of consent Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer, and does not allow any further 
collection of personal data .

[COMPANY_001] Confidential Page 10
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Amendment 05 (30- Aug-2018)
Amendment rationale
The primary purpose of the amendment is to provide further clarity  to the end of study  definition 
and trial timelines:
End of study  is defined as the date when all patients have completed their last assessment 
per protocol thirt y days after end of treatment visit 
Patients may  continue on study  treatment until need for a prematu re discontinuation 
criteria happened, [ADDRESS_4788] Visit occurred on 29- Mar-2013 . 45 total patients’ have been enrolled and 
[ADDRESS_4789] been implemented:
Updated author list of protocol to reflect the team currentl y working on/managing the 
protocol.
Glossary  of terms updated with personal data term and revised definition of withdrawal of 
consent.
Protocol Summary Section updated to match the body  of the protocol
.
Section 2.6, Risks and benefits : number of countries in which nilotini b is approved was updated.
Clarification that latest Investigator Brochure should be consulted was updated. H as been 
updated to clarify  that the [ADDRESS_4790].
Section 4.4, Early study termination : section has been updated per latest [COMPANY_001] standard .   
Definition of end of study  is defined in Section 4.3.
Section 6.1.[ADDRESS_4791] Visit in the study .

[COMPANY_001] Confidential Page 11
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Section [IP_ADDRESS] , Dose reduction guidelines for study  drug-related non hematologi cal toxicity : 
editorial update with reference to T able –2.
Table 6-2: updated to clarify  that dose modification applies to [ADDRESS_4792] 
[COMPANY_001] guidance .
Section 
6-3-1- 2: dose reduction guidelines for study  drug- related hematological toxicity have 
been added to harmonize guidance across [COMPANY_001]-sponsored Tasigna trials.
Table 6-3 summary  of dose reduction guidelines for study  drug - related hematological toxicity  
was added to harmonize guidance across [COMPANY_001] -sponsored Tasigna trials.
Section 6.3.2 Dose reduction guidelines for study  drug-related toxicity  for pediatric patients: 
editorial update with reference to table 6 -4.
Table 6-3: Hepato -biliary /Pancreas recommendation updated as guidance as to pancreas 
abnormality  are 
handled in a separate section of Table 6 -4.
Section 6.4.1, Prohibited concomitan ttherapy : additionnal guidance have been added as to 
CYP3A4 substrates and Drug with risk of Torsades de Pointe to hamonize with [COMPANY_001] 
sponsored Tasigna trials.Cardiac monitoring updated: Documentation will be kept in source 
document.
Section 6.6, Study drug preparation and dispensation : editorial update, Table 6 -5 reference was 
updated.
Section 6.6.1
, Study  treatment packaging and labelling : editorial update, Table 6- [ADDRESS_4793] Visit in the study and to clarify  study  duration .
Section [IP_ADDRESS], Criteria for premature patient withdrawal has been updated to clarify  that 
adverse event and disease progression based on physi cian assessment are captured as reason for 
premature patient withdrawal.
Section 7.1.[ADDRESS_4794] [COMPANY_001] 
template language.
Table 14-1, 14-2 and 14 - 3: the lists of CY3A4 inducers ,inhibitors and substrates have been 
updated according to the [COMPANY_001] Oncology  Clinical Pharmacology  Internal Memorandum, 
Drug -drug interactions (DDI) Database (last updated 2018). Reference to website where list of 
drug prolonging QT interval was updated.
Editorial modifications to correct ty pographical errors have been implemented as needed .

[COMPANY_001] Confidential Page 12
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Amendment 04 (27- Jul-2016)
Amendment rationale
The main purpose of the amendment is to correct an error in the language regarding pregnancy 
outcome collection. Pregnancy  outcom es from female partners of any males who took study  
treatment will not be collected in this study as nilotinib is not genotoxic and no effects on sperm 
count, motility , or on fertility  were noted in animal studies.
This roll -over stud y has been opened sinc e 29-Mar-[ADDRESS_4795] been implemented:
Section 6.3: Updated to clarify  that investigators should refer to the approved local 
label for 
additional details regarding dose modifications and recommendations. If no approved local 
label i s available, 
the SmPC or USPI [INVESTIGATOR_5306].
Section 8.4: Section has been updated. Pregnancy outcomes from female partners of an y mal es 
who took study  treatment will not be collected in this study .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Summary  of previous amendments
Amendment 03 (07-Apr-2016)
Amendment rationale
The main purpose of the amendment is:
To change the primary  endpoint to safety  in order to better characterize the lon g -term 
safet y of nilotinib
To include hepatitis B virus testing as one of the study  procedures, to identify  study  
patients who may  be at risk of hepatitis B reactivation. Reactivation of hepatitis B virus 
can occur in patients who are chronic carriers of this virus and are receiving a drug of the 
BCR -ABL TKI class such as nilotinib. Some cases involving BCR -ABL TKI resulted in 
acute hepatic failure or fulminant hepatitis leading to liver tran splantation or a fatal 
outcome.
To include the collection of all AEs (including non- serious AEs) and an investigator 
attestation of continued clinical benefit.
This roll-over stud y has been opened since [ADDRESS_4796] been implemented:
Section 2.1: The purpose of the study  has been updated to better characterize the long-term 
safet y of nilotinib in patients who are on nilotinib treatment in a [COMPANY_001] -sponsored study  and 
are benefitting from the treatment as judged b y the investigator.
Section 2.2: The rationale for the stud y design has been updated to better characterize the long -
term safet y of nilotinib in patients being treated in a curre nt [COMPANY_001] -sponsored study  and who 
are benefitting from treatment with nilotinib.
Section 2.6: Risks and Benefits section added per the new protocol template.
Table 3-1: Updated with revised study  objectives. The primary  objective is to evaluate long 
term safety  data. The secondary  objective is to evaluate clinical benefit as assessed by [CONTACT_1275].
Section 4.1: Updated to clarify  that study  is to better characterize the long -term safet y and that 
all adverse events and serious adverse events will be collected continuously  throughout the 
study . Additionall y at every  quarterl y visit, the investigator is required to confirm that the 
patient continues to have clinical benefit and may  continue receiving stud y treatment.
Section 5.3 Exclusion criteria #5 updated to clarify highl y effective contraception methods and 
to exclude sexually  active males unless they use a condom during intercourse while taking study 
drug and for 30 days after stoppi[INVESTIGATOR_056].

[COMPANY_001] Confidential Page 14
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Section 6.1.5: Updated to specify  that at every  quarterly visit, the investigator is required to 
confirm that the patient continues tohave clinical benefit and may continue receiving study 
treatment
Section 6.[ADDRESS_4797] been updated as a result.
Section 6.3.6 Hepatitis B reactivation was added to provide information on next steps for 
patients testing positive for hepatitis B virus.
Section 6.3.7 was added to provide follow- up information for drug -induced liver injury .
Section 6.4 added per the new protocol template. Subsequent section numbers were updated as 
a result.
Section 6.4.2 (Use of bisphosphonates) added per new protocol template; however, the section 
has been marked as “ Not applicable” for this study .
Section 7.1: Updated to include Hepatitis B testing at the next possible visit.
Table 7- 1: Updated to include investigator attestation of clinical benefit at every  quarterl y visit 
(12 weeks +/- 1week), collection of relevant medical history , hepatitis B testing, all adverse 
events , and stud y evaluation completion page .
Section [IP_ADDRESS]: Updated to include collecti on of relevant medical history .
Section 
7.1.3: Updated to specify  that the investigat or is required to confirm that the patient 
continues to have clinical benefit at every  quarterly  visit and may continue receiving study 
treatment.
Section 7.1.4: Highl y effective contraception definitions have been updated.
Previous section 7.1.4 updated t o Section 7.1.5 (Discontinuation of study  treatment).
Section 7.1.5 Updated to include the Study Evaluation Completion eCRF page to be completed 
for all patients at the end of the 30 day  safet y follow up.
Section 7.1.6 (Withdrawal of consent) and 7.1.8 (Lost to follow up) added per the new protocol 
template.
Section 7.1.7: Updated to include adverse events in safet y follow u p period.
Section 7.2.1: Updated to include investigator attestation of clinical benefit at every  quarterl y 
visit.
Section 7.2.2: Updated to clarify  that safet y will be monitored by [CONTACT_5337]. For details on AE collection and reporting, refer to Section 8.
Section [IP_ADDRESS] was added to provide info rmation on hepatitis B testing.
Section 7.2.3 (Pha rmacokinetics) and [IP_ADDRESS] (Analytical methods) added per the new template 
but both sections are “not applicable” for this study .
Section 8: Updated wit h new AE/SAE reporting process.

[COMPANY_001] Confidential Page 15
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Section 10: Updated statistical anal ysis section bas ed on revised stud y objectives.
The protocol summary  and list of abbreviations has also been updated based on the changes 
specified above.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and H ealth Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

[COMPANY_001] Confidential Page 16
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Amendment [ADDRESS_4798] enrolled into the study .
The main purpose for the amendment is:
To incorporate guidance for the management of:
Serum cholesterol increases
Blood glucose increases
Other cardiac risk factors
Ischemic vascular or ischemic cardiovascular events occurring in patients treated with 
nilotinib.
To update the exclusion criteria relating to male patient’s use highl y effective 
contraception to be aligned with the current Investigator Brochure.
To incorporate precaution of use for antacid drugs aligned with Tasigna®Prescribing 
Information and SmPC.
To define isch emic vascular and ischemic cardiovascular events as Clinical conditions of 
special interest, and their reporting to the Investigator.
To update the list of medications that can inhibit CYP3A4.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following changes were implemented in the protocol summary  as well as within the 
protocol sections below:
Section [IP_ADDRESS].1: Updated to include information on efficacy  response rate, ischemic vascular 
and ischemic cardiovascular event reported from the 60
-month analysis on the 
CAMN107A2303 study .
Section 4.1: Updated to clarify  that medical monitoring as clinically  indicated at the physician’s 
discretion should also include cardiovascular risk factors such as serum cholesterol and glucose 
levels amongst others.
Section 5.3: An exclusion criterion is updated to reflect that male patients are no longer required 
to use highly  effective contraception during the study  and for 30 days after the final dose of 
nilotinib.
Section 6.2: Updated to include guidelines for the management of patients in sub -section listed 
below (Sections 6.2.1 -6.2.5).
Sections 6.2.1 to 6.2.4: Sub-sections added to share guidance for the management of cholesterol 
increases, glucose increases, other cardiac risk factors and ischemic vascular or cardiovascular 
events.
Section 6.2.1: Updated to section 6.2.5 to include precaution for the use of antacid drugs and 
CYP3A4 inhibitors.

[COMPANY_001] Confidential Page 17
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Section 7.1.3: Updated to include guidelines for highl y effective contraception (as defined in 
exclusion criterion 5).
Section 8.1.1: Updated to clarify  that medical monitoring as clinically  indicated at the 
physician’s discret ion should include cardiovascular risk factors such as serum cholesterol and 
glucose levels amongst others. Update also includes the education of patient’s on the reporting 
of clinical conditions of special interest.
Section 8.1.3: Updated to include guida nce on Clinical conditions of special interest.
Section 14.1: Appendix [ADDRESS_4799] of CYP3A4 inhibitors.
IRBs /IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Amendment [ADDRESS_4800] been enrolled into the study  and started 
on treatme nt.
This amendment is a global amendment and has been implemented to address the following 
changes for the stud y:
To add monthly  pregnancy  tests for female patients of child bearing potential to reflect the 
requirement of highl y effective contraception for patients on nilotinib treatment.
To add language clarify ing that dose modifications will be based on guidelines provided in 
the parent protocol, as well as investigator’s judgment.
To add language clarify ing that should treatment with strong CYP3A4- inhibitors be 
required, it is recommended that therap y with nilotinib be interrupted if possible.
To add language clarify ing the strengths of nilotinib allowed in the study  to ensure 
patients can have access to the same strengths as specified in the parent protocol.
To clarify  that patients who are pregnant, withdrawn consent or have died must be 
withdrawn from the study.
To address other administrative and t ypographical corrections noted in the original 
protocol.
Changes to the protocol
Changes to s
pecific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following changes were implemented in the protocol summary  as well as within the 
protocol sections below:
Section 2.3: Updated to clarify  additional strengths of nilotinib can be provided if specified in 
the parent protocol.
Section 6.1.1: Updated to clarify  additional strengths of nilotinib can be provided if specified 
in the parent protocol.
Section 6.2: Updated to clarify  that dose modifications will be based on guidelines provided in 
the parent protocol as well as investigator’s judgment.
Section 6.2.1: Updated to clarify  that should treatment with strong CYP3A4- inhibitors be 
required, it is recommended that therapy  with nilotinib be interrupted if possible.
Table 6- 2: Additional strengths of nilotinib can be provided if specified in the parent protocol.
Table 7- 1: Monthly  pregnancy  testing added in the Visit evaluation table.
Section 7.1.3: Updated to add a section regarding pregnancy testing for female patients of child 
bearing potential.
Section [IP_ADDRESS]: 
Updated to clarify  that patients who are pregnant, withdraw consent or have 
died must be withdrawn from the study .

[COMPANY_001] Confidential Page 19
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
IRBs /IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

[COMPANY_001] Confidential Page 20
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Protocol Summary
Brief title An open label, multi -center nilotinib roll -over protocol 
for patients who have completed a previous [COMPANY_001]-
sponsored nilotinib study and are judged by [CONTACT_5338].
Data analysis The assessment of safety will be based mainly on the
frequency of AEs and SAEs . Proportion of patients 
with clinical benefit as assessed by [CONTACT_5339]. As needed, 
safety information on patients from this protocol will 
link to the patient identifiers from the pare nt protocol .
Efficacy assessments At every quarterly visit, the investigator is required to 
confirm that the patient continues to have clinical 
benefit and may continue receiving study treatment
Exclusion criteria Patient has been permanently discontinue d from 
nilotinib study treatment in the parent study due to 
unacceptable toxicity, non -compliance to study 
procedures, withdrawal of consent or any other 
reason.
Patient has participated in a [COMPANY_001] sponsored 
combination trial where nilotinib was dispens ed in 
combination with another study medication and is still 
receiving combination therapy.
Inclusion criteria Patient is currently enrolled in a [COMPANY_001] - sponsored, 
Oncology Global Development & Global Medical 
Affairs (OGD&GMA) study receiving nilotinib and has 
fulfilled all their requirements in the parent study.
Patient is currently benefiting from the treatment with 
nilotinib, as determined by [CONTACT_093].
Patient has demonstrated compliance, as assessed 
by [CONTACT_093], with the parent study protocol 
requirements.
Investigation type Drug
Investigational and reference therapy Nilotinib , ≤ 800 mg/day.
Key words Tasigna roll -over study for continued use of nilotinib to 
patients receiving nilotinib in a [COMPANY_001] -sponsored 
Oncology OGD&GMA stud y which has reached its 
objectives and who are benefiting from treatment with 
nilotinib .
Other assessments Not applicable.
Population Male and female patients, who are currently enrolled 
in a [COMPANY_001] -sponsored, Oncology OGD&GMA 
nilotinib study, are benefiting from treatment with 
nilotinib and have fulfilled all their requirements in the 
parent study. All objectives of the parent study must 
have been reached, and the study must be in the 
process of being completed & reported. 
Approximately 100 patients may enroll into this study.
Primary Objective(s) and Key Secondary Objective
Key Secondary ObjectiveTo evaluate long term safety data (SAEs and AEs). 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Protocol number CAMN107A2409
Purpose and rationale The purpose of this study is to better characterize long -term safety data nilotinib
in patients who are on nilotinib treatment in a [COMPANY_001]-sponsored, Oncology
Global Development & Global Medical Affairs (OGD&GMA ) study and are 
benefiting from the treatment as judged by [CONTACT_093] .
Safety assessments All adverse events and serious adverse events will be collected continuously 
throughout the study. Patients will be tested once for the following hepatitis B 
serologic markers: hepatitis B surface antigen (HBs Ag) and antibodies to 
hepatitis B core antigen (HBc Ab / anti HBc).
For the safe and effective use of Tasigna, medical monitoring should be 
performed as clinically indicated at the physician’s discretion; this should also 
include monitoring of cardiovascular risk factors such as serum cholesterol and 
glucose levels amongst others.
Secondary Objectives To evaluate clinical benefit as assessed by [CONTACT_5340] , 
IV.
Study design This is a multi -center, open label, phase IV study to better characterize the long -
term safety of nilotinib to patients being treated in current [COMPANY_001]-sponsored, 
Oncology OGD&GMA studies and who are benefiting from treatment with 
nilotinib.
There will be no screening period for this study. At the enrollment visit the patient 
will be consented to the study and eligible patients will start their treatment with 
nilotinib. At this time, a 3 month supply of nilotinib will be dispensed to the 
patient/or as per local practice.
Patients must return to the study center on a quarterly basis ( every 12 weeks +/-
1 week ) for resupply of study medication at which time drug dispensing and 
adverse event information will be collected. The patient may return to the clinic at 
any given time as per standard of care, however, only data from the quarterly 
visits will be recorded. All adverse events and serious adverse events will be 
collected continuously throughout the study. Patients will be tested once for the 
following hepatitis B serologic markers: hepatitis B surface antigen (HBs A g) and 
antibodies to hepatitis B core antigen (HBc Ab / anti HBc). For the safe and 
effective use of Tasigna, medical monitoring should be performed as clinically 
indicated at the physician’s discretion, this should also include monitoring of 
cardiovascular risk factors such as serum cholesterol and glucose levels 
amongst others.
Patients will continue to be treated until they are no longer benefiting from 
nilotinib treatment, develop unacceptable toxicities, withdraw consent, are non -
compliant to the protocol, the investigator feels it is no longer in the patient’s best 
interest to continue nilotinib therapy or the patient dies, whichever comes first.
A patient will reach the end of study when nilotinib treatment is permanently 
discontinued and the end of treatment visit has been performed.
The study is expected to remain open for treatment for [ADDRESS_4801] 
completed a previous [COMPANY_001] -sponsored nilotinib study and are judged by [CONTACT_5341].

[COMPANY_001] Confidential Page 22
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_5307]
1.1.1 Overview  of chr onic my eloid leukemia (CML)
Chronic myeloid leukemia (CML) is a hematologic disorder associated with a specific 
chromosomal translocation known as the Philadelphia (Ph) chromosome detected in 95% of 
patients ( Nowell 1960, Rowley  1973). The molecular consequence of the translocation is the 
fusion of the ABL proto -oncogene to the BCR gene resulting in the production of an acti
vated 
form of the Abl protein- tyrosine kinase (Bartram 1983, Heisterkamp 1983 ). Clinically , CML 
progresses through three distinct phases of increasing refractoriness to therapy : chronic phase 
(CP), accelerated phase (AP) and blast crisis (BC). Most patients however present in the chronic 
phase at the time of diagnosis, characterized by  [CONTACT_5342] y and leukocy tosis with generall y 
few symptoms. CML  comprises 15% of adult leukemias, with an approximate incidence of 1-
2 per 100,000 per year and median age of presentation of 45 to 55 years of age ( Weisberg 2006,
Frazer 2007). Tyrosi ne kinase inhibitors that inhibit BCR -ABL (TKIs) are the gold standard 
treatment for BCR -
ABL positive CML . Imatinib (Glivec®, Gleevec®; [COMPANY_001] Pharma AG, 
Basel, Switzerland) was the first TKI approved for this indication and revolutionized the 
treatment of CML. Imatinib is the TKI with the longest follow -up with estimated progression -
free survival of 81%, freedom from progression to AP/BC of 92% and estimated overall 
survival (OS) of 85% at 8 yrs for newl y diagnosed CP CML  patients (93% when only CML -
related deaths and those prior to stem cell transplantation (SCT) were considered) (Deininger 
2009).
Nilotinib (Tasigna®; [COMPANY_001] Pharma AG, Basel, Switzerland) and dasatinib (Spry cel®; Bristol -
Myers Squibb , Wallingford, CT, [LOCATION_003]) are approved for treatment of patients with Ph+ CML 
who have failed prior therapi[INVESTIGATOR_5308]. Both 
nilotinib and dasatinib have recentl y demonstrated superiority  over imatinib in head -to-
head 
clinical studies in patients newly  diagnosed with Ph+ CML  (Kantarjian 2010 ,Saglio 2010 ).
1.1.2 Overview  of gastrointestinal stromal tumors (GIST)
Gastro intestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal (GI) tract and are thought to originate from the interstitial cells of Cajal. GI STs 
are malignant tumors most commonly  resulting from activating mutations in the receptor 
tyrosine kinase KIT (CD117) or the platelet -derived growth factor receptors α (PDGFRα) 
(Demetri et al 2010). Approximately  85% of KIT (CD117) -positive GISTs harbors an activating 
mutation in the KIT oncogene and 5-8% of GISTs have mutated PDGFRα gene . Mutations in 
KIT exon [ADDRESS_4802] common (67%) while KIT exon 9 mutations are found in 10 -12% of 
GISTs. Mutations in KIT exons 13 and 17 are rare. The remaining cases harbor no mutation 
and are referred to as “Wildty pe” GIST 
(Corless and Heinrich 2008 ).
GISTs can arise anywhere along the GI tract but are most common in the stomach and small 
intestine (Demetri et al 2010 ). The majorit y of KIT exon [ADDRESS_4803] PDGFRα mutations are found in gastric GI STs. KIT exon 1 1 mutations are 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
distributed throughout the GI tract. Response to systemic therapi[INVESTIGATOR_5309] /inoperable 
disease setting is related to the identified activating mutations in GIST and the development of 
subsequent resistance mutations ( Corless and Heinrich 2008 ).
The mainstay  of therap y for patients with primary  GIST is surgical resection. However, surgery 
alone is generall y not curative; the 5-year disease specific survival is reported to be 54%.
Recurrence rates exceeding 50% within [ADDRESS_4804] and 
approximating 90% after re -excision ( DeMatteo et al 2000 ), underscored the need for effective 
postoperative treatment.
Imatinib is the first-line therap y for metastatic GIST with a median progression free survival 
(PFS) reported between 18 months (Phase III) and 29 months (Phase II) and a median overall 
survival of 57 months (Verweij 2004, Blanke 2008a , Blanke 2008b, Bertucci 2012). For patients 
whose disease has progre ssed during, or who are intolerant to imatinib therap y, sunitinib 
(Sutent®; [COMPANY_007]) is the available second line treatment ( Demetri 2006).
Nilotinib also inhibits the tyrosine kinase activity of KIT and PDGFRα which are associated 
with GISTs. However, although nilotinib and imatinib exhibit similar potencies against the KIT 
and PDGFR target enzymes, they exhibit major differences in cell transport. Thus Prenen 
(Prenen et al 2006 ) has demonstrated that in two GIST cell lines, intracellular levels of nilotinib 
are much higher (7- 10 fold) than those of imatinib, at physiologicall y relevant concentrations 
of the two agents. The ability  of nilotinib to achiev e higher intracellular concentrations in GIST 
cells might be the reason that nilotinib has shown anti-proliferative activity  at physiologicall y 
relevant concentrations in imatinib -resistant GI ST48 and GIST430 cells ( Dileo et al 2006 ).
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  ofnilotinib
Nilotinib (Tasigna®, AMN107) is a highl y potent and selective inhibitor of both wild -type and 
imatinib -resistant forms of the tyrosine kinase activity  of the BCR -ABL oncoprotein both in 
cell lines and in primary  Philadelphia -chromosome positive (Ph+) leukemia cells. BCR -ABL is 
a constitutively  active tyrosine kinase and drives the pathology  of chronic myelogenous 
leukemia, a myeloproliferative disorder characterized by a clonal expansion of hematopoietic 
stem cells expressing the BCR -ABL gene. The therapeutic concept of BCR -ABL tyrosine 
kinase inhibition is an effective treatment modality  for Ph+ CML  as inhibition of BCR -ABL 
kinas e activity  with nilotinib results in apoptosis of Ph+ CML  cells.
Nilotinib is currently  approved for the treatment of adult patients with Philadelphia 
chromosome positive (Ph+) chronic myeloid leukemia in chronic phase and accelerated phase 
resistant to or intolerant to at least one prior therapy including imatinib and for the treatment of 
adult patients with newly diagnosed Ph+ CML  in CP.
Nilotinib also inhibits a small number of receptor tyrosine kinases, including the stem cell factor 
kinase (KIT), plate let-derived growth factor kinases (PDGFRα and PDGFRβ), colon y 
stimulating factor receptor kinase (CSF -1R), discoidin domain receptor kinases (DDR1 and 
DDR -2) and ephrin receptor kinase (EphB4). Consequently , the activity  of nilotinib has also is 
also being explored in other potential indications.

[COMPANY_001] Confidential Page 24
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
[IP_ADDRESS] Non- clinical experience
For information on pre-clinical toxicity  please refer to the current nilotinib [Investigator 
Brochure] (IB).
[IP_ADDRESS] Clinical experience
[IP_ADDRESS].1 Human safety and tolerability data
Imatinib -naïve CML patient s:
The efficacy  of nilotinib in patients with newly  diagnosed Ph+ CML -CP has been evaluated in 
a phase III multi- center open label, randomized study  (CAMN107A2303/ENESTnd) 
comparing nilotinib to imatinib in adult patients with newly  diagnosed CML -CP. This study  is 
ongoing and showed continuing superiorit y of nilotinib vs. imatinib at 12, 24, 36, 48 and 60 
months follow -up in terms of cytogenetic and molecular responses. A total of 846 newly  
diagnosed CML -CP patients were randomized into the study  of which 484 patients were still 
receiving core treatment as 
of the 60-month cut-off date (141 patients (49.8%) in the imatinib 
arm, 169 patients (59.9%) in the nilotinib 300 mg BID arm and 174 patients (61.9%) in the 
nilotinib 400 mg BID arm). A total of 362 patients discontinued core study  treatment. The study 
met its primary  efficacy endpoint at the 12-month analysis time point: the MMR rate was 
significantl y higher in the nilotinib arms compared to the imatinib arm. By 60 months, the MMR 
rate remained higher in the nilotinib arms than in the imatinib arm, indicating that the superiority 
of both nilotinib arms over the imatinib arm persists with longer follow -up. Furthermore, the 
proportions of patients achieving molecular response of ≤ 0.01% and ≤ 0.0032% b y 60 mo nths 
were higher in the nilotinib arms than in the imatinib arm.
Ischemic Vascular and Ischemic Cardiovascular Events Reported for 
CAMN107A 2303 (ENESTnd Study):
Newl y-diagnosed or worsened Ischemic Vascular and Ischemic Cardiovascular Events such as 
Ischem ic Heart Disease (IHD), Ischemic Cerebrovascular Events (ICVE) or Peripheral Artery  
Occlusive Disease (PAOD) have occurred in a relatively  small number of CML -CP patients 
while on study medication. However, such events have been reported with higher freque ncy on 
the nilotinib treatment arms compared with the imatinib treatment arm. Up to the data cut-off 
for the 60 month analy sis (30-Sep- 2013), the number of patients reported with these events is 
as follows:
Nilotinib 300 mg BID: IHD, 11 (3.9%); ICVE, 4 (1. 4%); PAOD, 7 (2.5%)
Nilotinib 400 mg BID: IHD, 24 (8.7%); ICVE, 9 (3.2%); PAOD, 7 (2.5%)
Imatinib 400 mg QD: IHD, 5 (1.8%); ICVE, 1 (0.4%); PAOD, 0 (0.0%)
The majority  of reported ischemic vascular and ischemic cardiovascular events were in patients 
with a ssociated risks (e.g., advanced age, hy pertension, hy perlipi[INVESTIGATOR_035], hy percholesterolemia, 
smoking, diabetes mellitus, pre-existing peripheral vascular disease). The background 
incidence of these events has not been established for the CML patient population .
A detailed description of efficacy  and safet y data can be found in the current nilotinib 
[Investigator’s Brochure].

[COMPANY_001] Confidential Page 25
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Imatinib -resistant or -intolerant hematologic diseases:
Data from a Phase I/II [CAMN107A2101] open -label study  indicated that nilotinib treatment 
resulted in hematologic and cytogenetic responses in patients who had received prior TKIs 
(including imatinib). I n this study  a total of 321 CML -CP patients were evaluated for efficacy. 
Of these, 70.4% were imatinib -resistant and 29.6% were imatini b-intolerant. Patients were 
treated with nilotinib 400 mg b.i.d. Overall survival at 24 months was 87%. In terms of efficacy , 
165 
patients (51.4%) achieved a major cytogenetic response (MC yR), which was the primary 
efficacy  variable. This study  also analy zed the effect of 400 mg b.i.d. nilotinib in a group of 49 
chronic phase CML  patients with prior TKI treatment other than imatinib. At 24 months follow -
up, study  discontinuation rate was 69.4% (38.8% due to disease progression and 12.2% due to 
AEs). Efficac y parameters included 77.1% complete hematological response (CHR) for those 
not in CHR at baseline, 42.9% MCyR, 22.4% complete cy togenetic response (CCyR) and 89% 
overall survival.
The median average daily  dose of nilotinib for CML -CP patients was 788.[ADDRESS_4805] 
frequentl y reported (>10%) drug-related adverse events (AEs) in CML -CP patients, based on 
24-month data and 321 patients, included rash (30.8%), thrombocy topenia (28.0%), pruritus 
(26.2%), nausea (24.6%), fatigue (20.2%), headache (17.8%), neutr openia (15.0%), 
constipation (13.4%), anemia (13.1%), lipase increased (12.8%), vomiting (12.8%), diarrhea 
(12.1%), alanine aminotransferase increase (10.6%), myalgia (10.3%). In CML -CP patients, the 
most frequent severe adverse events (SAEs) were thromboc ytopenia (3.4%), neutropenia 
(2.2%), angina pectoris (2.8%) and p yrexia (2.5%).
Adverse events that were associated with discontinuation of treatment with nilotinib were 
reported in 21.2% of all patients and 16.8% of these events were of Grade [ADDRESS_4806] frequent AEs associated with discontinuation were neutropenia and thrombocy topenia, 
which occurred in 10 (3.1%) patients each.
The most frequent Grade 3 or 4 AEs were neutropenia (3.1%), thrombocytopenia (2.8%) and 
thrombocy temia (1.2%); all other events occurred at a frequency  lower than 1%.
A detailed description of efficacy  and safet y data can be found in the current nilotinib 
[Investigator’s Brochure].
[IP_ADDRESS].2 Newly diagnosed GISTs:
The in vitro activity  of nilotinib in imatinib resistant GIST cell lines has been confirmed in 
[CAMN107A2103] a Phase I study  in patients with imatinib -resistant or intolerant GISTs. As 
nilotinib is not subject to the same cellular transport mechanisms as imatinib, itis effective in 
both imatinib -sensitive and imatinib -resistant GIST cells. The median progression free survival 
of nilotinib in imatinib -resistant GIST patients was 168 (5.6 months) days in the 
[CAMN107A2103] study.
With the success of the CAMN107A2103 itwas reasonable to assume that nilotinib may  have 
similar or improved efficacy  over imatinib in GIST patients.
In the phase III study  [CAMN107G2301] patients with unresectable and/or metastatic GIST 
who have either not received prior therapy  with a TKI or who have recurrent GIST after 
stoppi[INVESTIGATOR_5310] , were randomized to either nilotinib or imatinib therap y. The primar y 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
objective of this study is to compare PFS of nilotinib and imatinib when used as initial therapy 
in this patient population.
Howev er the study had to be closed to further recruitment at the request of the Data Monitoring 
Committee since the futility  boundary  was exceeded in an interim futility  analysis (e.g. this 
means that there was an extremely  low likelihood that continuing with the study  would have 
resulted in a significantly positive outcome in favor of nilotinib). There are no plans to initiate 
new studies of nilotinib in the GI ST patient population.
In general, the safet y profile in GIST patients was similar to that in CML patients, with the 
exception of a lower incidence of hematologic toxicity .
A detailed description of efficacy  and safet y data can be found in the current nilotinib 
[Investigator Brochure].
[IP_ADDRESS].3 Clinical pharmacokinetics and pharmacodynamics
The relationship of systemic exposure (Cmax, AUC) over the range of 50 to 1200 mg nilotinib 
given once a day was assessed in patients with imatinib resistant or intolerant CML. With once 
daily  dosing stead y-state nilotinib Cmaxand AUC increased with increasing dose from 50 mg to
400 mg in a generally  dose -proportional manner, but appeared to plateau at dose levels of 400 
mg and higher. Using a twice daily  dosing regimen partially  overcame the dose-limiting 
exposure, with daily  steady -state serum nilotinib exposure at 400 mg twice daily  dose (b.i.d.) 
being approximately  35% greater than with 800 mg once dail y dose (q.d.). However, there was 
no further relevant increase in nilotinib exposure observed with the administration of 600 mg 
b.i.d. With multiple oral doses of nilotinib, steady-state conditions were achieved by [CONTACT_4475] 8 after 
initiating nilotinib treatment. There was a 2-fold or 3.8-fold accumulation with q.d. or b.i.d. 
dosing, respectivel y. The median time to reach Cmaxof nilotinib (tmax) was 3 hours. Terminal 
elimination half -life of nilotinib was estimated to be approximately  17 hours.
The bioavailability  of nilotinib is increased when the drug is given with a meal. 
Compared to 
the fasted state, nilotinib AUC is increased by 15% (administered 2 hours after a light meal), 
29% (30 minutes after a light meal), or 82% (30 minutes after high fat meal), and the C max
increased by 33% (2 hours after a light meal), 55% (30 minutes after a light meal), or 112% (30 
minutes after high fat meal). Concurrent intake of grapefruit juice increased the nilotinib C max
by 60% and AUC 0-∞by 29%, but the t maxand t 1/2were not alte red.
Nilotinib is metabolized by [CONTACT_4852], primaril y via CYP3A4. Metabolism of nilotinib leads to 
the formation of several minor metabolites, none of which contributes significantl y to the 
pharmacological activity  of the drug. Unchanged nilotinib represen ts the predominant 
circulating component in serum (approximately 88% of the total drug -related serum exposure). 
Strong inhibitors or inducers of CYP3A4 can significantl y alter the pharmacokinetics and 
systemic exposure of nilotinib in humans.
Nilotinib is a substrate of P -gp, but is neither a Multi -resistance protein 2 ( MRP2) nor a Breast 
Cancer Resistance Protein (BCRP) substrate.

[COMPANY_001] Confidential Page 27
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
2 Rationale
2.1 Stud y rationale and purpose
The purpose of this study  is tobetter characterize the long-term safet yof nilotinib in patients 
who are on nilotinib treatment in a [COMPANY_001] -sponsored, Oncology  Global Development & 
Global Medical Affairs (OGD&GMA ) study  and are benefiting from the treatment as judged 
by [CONTACT_093]. Which parent studies are eligible to participate in the roll-over study  will 
be decided by [CONTACT_5343], Investigator initiated trials (IITs) will not be included. All objectives 
of the parent study  must have been reached, and the parent study  must be in the process of being 
completed and reported.
Patients will continue to receive nilotinib until one of the following occurs: the patient is no 
longer benefiting from the treatment, unacceptable toxicity  develops, consent is withdrawn, 
there is non -compliance with the protocol, the investigator feels it is no longer in the patient’s 
best interest to continue therap y, or the patient’s death.
2.2 Rationale for the study  design
This is a multi -center, open label, phase IV study  to better characterize the long -term safety  of 
nilotinib inpatients being treated in a current [COMPANY_001] -sponsored, Oncology  OGD&GMA study 
and who are benefiting from treatment with nilotinib.
The study  will not include a screening phase as patients will transfer directl y from parent studies 
and will commence treatment with nilotinib as soon as they are consented and meet the 
inclusion criteria of the roll -over protocol.
2.[ADDRESS_4807] gelatin capsules (HGC). Additional 
strengths of nilotinib can be provided if specified in the parent protocol. The starting dose of 
nilotinib should be the same dose which was given in the parent nilotinib study . After the 
starting dose, the dose of nilotinib is based on the investigator’s judgment.
Nilotinib in different formulations and stren gths can be used in the roll-over study  once they 
are approved and marketed.
2.4 Rationale for choice of combination drugs
Not applicable.
2.5 Rationale for choice of comparators drugs
Not applicable.
2.6 Risks and benefits
Tasigna is a marketed drug since 2007. Tasigna has shown considerable efficacy  for the 
indications of newly  diagnosed Philadelphia chromosome positive chronic myelogenous 
leukemia (Ph+ CML ) in chronic phase (CP) and chronic phase and accelerated phase (AP), Ph+ 
CML  in adult patients resistant to or intolerant to previous therapy including imatinib. Tasigna 

[COMPANY_001] Confidential Page 28
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
has also shown considerable efficacy  for resistant patients who have failed treatment with 
Glivec and in patients with newly  diagnosed Ph+ CML  (CP). Based on the results of clinical 
trials such as [CAMN107A2101 ]and [CAMN107A2303 ], nilotinib is approved worldwi de in 
130countries.
Please refer to the latest nilotinib [Investigators’ Brochure] for the known anticipated safet y 
concerns of the study drug; dosage and administration; precautions and potential risks; and use 
in specific populations (including pregnancy , lactation and fertility , elderly , renal and hepatic 
impairment and overdosage). The subjects to be enrolled will be patients currently  experiencing 
clinical benefit as attested by [CONTACT_5344]-term safet y of the 
compound. These subjects will get the opportunity  to continue to derive medical benefit from 
the treatment with nilotinib by [CONTACT_4907] .
The risk to subjects in this trial may be minimized by [CONTACT_5345], regular clinical monitoring and proactive dose modification and toxicity 
management.
In case patients do not tolerate the dosing schedule, dose adjustments are permitted in order to 
keep the patient on study drug. Dosing should always be adjusted/discontinued if the physician 
determines it is in th e best interest of the patient.
Patients will continue to be treated in the roll -over protocol until they  are no longer benefiting 
from the nilotinib, develop unacceptable toxicities, withdraw consent, are non -compliant to the 
protocol, the investigator feels it is no longer in the patie nt’s best interest to continue therap y, 
pregnancy  occurs or the patient 
dies, whichever comes first. The study  is expected to remain 
open for treatment for [ADDRESS_4808] access to nilotinib without interruption of treatment in 
accordance with local regulation.
It is understood that doses and schedule of nilotinib treatment will be different for each patient 
(depending on the parent study ).
There may be unforeseen risks with nilotinib which could be serious. Refer to the latest nilotinib 
[Investigator ’s Brochure].
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Table 3-1 Objectives and related endpoints
Objective Endpoint Analysis
Primary Refer to Section 10.4
To eval uate long -term safety data ( SAEs and 
AEs)Frequenc y and severity of AEs/SAEs
Secondary Refer to Section 10.5.2
To evaluate clinical benefit as assessed by [CONTACT_5346] 30
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
4 Study  design
4.1 Description of study  design
This is a multi -center, open label, phase IV study  to better characterize the long -term safety of 
nilotinib inpatients being treated in current [COMPANY_001] -sponsored, Oncology  OGD&GMA studies 
and who are benefiting from treatment with nilotinib.
There will be no screening period for this study . At the enrollment visit the patient will be 
consented to the study  and eligible patients will start their treatment with nilotinib. At this time, 
a 3 month supply  of nilotinib will be dispensed to the patie nt/or as per local practice.
Patients must return to the study center on a quarterly  basis (12 weeks +/ -1 week), for resuppl y 
of study  medication at which time limited drug dispensing information will be collected. The 
patient may return to the clinic at any given time as per standard of care, however, only the 
quarterl y visits will be recorded. All adverse 
events and serious adverse events will be collected 
throughout the study . For the safe and effective use of Tasigna, medical monitoring should be 
perfo rmed as clinically indicated at the physician’s discretion; this should also include 
monitoring of cardiovascular risk factors such as serum cholesterol and glucose levels amongst 
others . Patients will continue to be treated until they are no longer benefi ting from nilotinib 
treatment, develop unacceptable toxicities, withdraw consent, are non-compliant to the protocol, 
the investigator feels it is no longer in the patient’s best interest to continue nilotinib therap y or 
the patient dies, whichever comes first.At every quarterl y visit (12 weeks +/-1 week), the 
investigator is required to confirm that the patient continues to have clinical benefit and may 
continue receiving stud y treatment.
A patient will reach the end of study  when nilotinib treatment is p ermanently discontinued and 
the end of treatment visit has been performed.
The study  is expected to remain open for [ADDRESS_4809] access to nilotinib without interruption of treatment 
in accordance with local regulation.
Figure 4 -1 Study  design

[COMPANY_001] Confidential Page 31
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
4.[ADDRESS_4810] assessment for each patient is the 
follow -up assessment that occurs 30days after the patient’s last dose of study  treatment. 
Patients may continue on study  treatment until one ofthe following criteria is met, whichever 
comes first:
Discontinuation of study  treatment per a
t least one of the premature patient withdrawal 
criteria are met ( see Section 7.1.5 and Section [IP_ADDRESS])
[ADDRESS_4811] Patient’s 
First Visit into this clinical trial
Study  treatment becomes commerciall y available and is reimbursed in the respective
indication.
Should nilotinib not be commercially  available to patients at end of study  due to local 
regulations, [COMPANY_001] will make every  effort to ensure that patients benefiting from treatment 
continue to have access to nilotinib without interruption of treatment in accordance with local 
regulation.
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7for a prematurel y withdrawn patient. The investigator may be 
informed of additional procedures to be followed in order to en
sure that adequate consideration 
is given to the protection of the patient’s health interests. The investigator will be responsible 
for informing IRBs and/or ECs of the early  termination of the trial.
[ADDRESS_4812] to meet all of the following criteria:
1.Patient is currently
 enrolled in a [COMPANY_001] -sponsored, Oncology  Clinical Development & 
Global Medical Affairs study  receiving nilotinib and has fulfilled all their requirements in 
the parent stud y.
2.Patient is currently  benefiting from the treatment with nilotinib, as determined by  [CONTACT_1275].

[COMPANY_001] Confidential Page 32
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
3.Patient has demonstrated compliance, as asses sed by  [CONTACT_093], with the parent 
study  protocol requirements.
4.Willingness and ability  to comply  with scheduled visits, treatment plans and any  other 
study  procedures.
5.Written informed consent obtained prior to enrolling in roll -over study .
If consent cannot be expressed in writing, it must be formall y documented and 
witnessed, ideall y via an independent trusted witness.
5.[ADDRESS_4813] not meet anyof the following criteria:
1.Patient has been permanently  discontinued from nilotinib treatment in the parent study  due 
to unacceptable toxicity , non -compliance to stud y procedures, withdrawal of consent or 
any other reason.
2.Patient has participated in a [COMPANY_001] sponsored combination trial where nilotinib was 
dispensed in combination with another study
 medication and patient is still receiving 
combination therap y.
3. Patients who are currently  receiving treatment with any  medications that have the 
potential to prolong the QT interval or inducing Torsade de Pointes a nd the treatment 
cannot be either safely  discontinued at least one week prior to nilotinib treatment or 
switched to a different medication prior to start of nilotinib treatment and for the duration 
of the study  (Please see Appendix [ADDRESS_4814] of agents that prolong the QT interval).
4.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination o f gestation, confirmed b y a positive hcG 
laboratory  test.
5.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they are using highly  effective methods of contraception 
during the stud y and for 30 days after the final dose of nilotinib. Highly effective
contraception is defined as either:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulat ion 
methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n 
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level assessment.
Male sterilization (at least 6 months prior to enrolling). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_5311] a minimum of 3 months before taking stud y treatment.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Women are considered post -menopausal and not of child bearing potential if they  
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (i.e. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or without hy sterect omy), total h ysterectom y, or tubal 
ligation at least six weeks ago. In the case of oophorectom y alone, onl y when the 
reproductive status of the woman has been confirmed by  [CONTACT_5347].
If a stud y patient becomes pregnant or suspects being pregnant during the study  or 
within 30 day s after the final dose of nilotinib, the I nvestigator/Study  Doctor needs to 
be informed immediatel y and ongoing stud y treatment with nilotinib has to be 
stoppe d immediately .
6 Treatment
6.1 Stud y treatment
Terms related to study  treatment are defined below:
Study  treatment and investigational treatment refer to nilotinib.
6.1.1 Dosing regimen
Table 6-1 Dose and treatment schedule
Study  treatmentsPharmaceutical form and 
route of administration DoseFrequency  and/or 
Regimen
Nilotinib /AMN107 *Hard Gelatin Capsule for 
oral use≤800 mg **Daily
* Different formulations and strengths can be used once they are approved and marketed.
**If total daily dose is [ADDRESS_4815] be recorded by [CONTACT_5348]’s site.
The starting dose of nilotinib should be the same as the last dose that was given in the parent 
nilotinib study . After this, the dose of nilotinib is based on the investig ator’s judgment.
Nilotinib must NOT be taken with food. No food should be consumed for at least [ADDRESS_4816] one hour after the dose is taken. This instructi on should be followed if patient is to take 
nilotinib once or twice a day. If nilotinib is taken twice a day (when 300 -400 mg b.i.d) patients 
should be instructed to take nilotinib each morning and evening approximately  12 hours apart.
Each dose of nilotinib should be taken with a glass of water. If the morning or the evening dose 
is delay ed for more than 4 hours, the patient should skip this dose and resume dosing with the 
next dose as per the original schedule in order to prevent overdosing.

[COMPANY_001] Confidential Page 34
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Niloti nib can be provided as local commercial material or global suppl y wh ere appropriate and 
as per local regulations. As per [COMPANY_001] procedures, investigational treatment will only be 
shipped directl y to the investigational sites.
Nilotinib in different formu lations and strengths can be used once they are approved and 
marketed.
Refer to the latest [Investigator Brochure] for nilotinib dosing instructions and storage 
conditions.
6.1.[ADDRESS_4817] dose that was given in the parent 
nilotinib study . After this, the dose of nilotinib is based on the investigator’s judgment.
6.1.5 Treatment duration
Patients will continue to be treated until they  are no longer benefiting from nilotinib treatment, 
develop unacceptable toxicities, withdraw consent, are non-compliant with the protocol, the 
investigator feels it is no longer in the patient’s best interest to continue nilotinib therapy ,the 
patient 
dies, 10years after First Patient First Visit into this clinical trial,or until study  treatment 
becomes commercially available and reimbursed in the respective indication ,whichever comes 
first. At every quarterly  visit (12 weeks +/ - 1 week) , the investigator is required to confirm that 
the patient continues to have clinical benefit and may continue receiving study  treatment. A 
patient will reach the end of the roll-over study  when nilotinib treatment is permanentl y 
discontinued.
6.[ADDRESS_4818] dose that was given in the parent 
nilotinib study . After this, the dose of nilotinib is based on the investigator’s judgment.
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For the purpose of these dose reduction guidelines, toxicity  is defined as any adverse event (AE) 
which is, with reasonable likelihood according to investigator’s judgment, caused by [CONTACT_5349].

[COMPANY_001] Confidential Page 35
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
According to International Conference on Harmonization (ICH) E6 the investigator is 
responsible for all trial- related medical decisions.
During and following a patient’s participation in a trial, the investigator should ensure that 
adequate medical care is provided to a patient for any adverse events, including clinicall y 
significant laboratory  values, related to the stud y drug.
If multiple dose-reducing toxicities are present, the greatest dose reduction schedule must be 
used.
Additional guidelines for the management of patients including recommendations for the 
clinical management of cardiovascular risk factors and related events are listed in the sub
-
sections below.
These changes must be recorded on the Dosage Administration Record CRF.
[IP_ADDRESS] Dose reduction guidelines for study  drug -related non -hematological 
toxicity  and for ischemic vascular and cardiovascular events 
regardless of study  drug relationship
A summary of dose reduction guidelines for study drug- related non- hematological toxicity  and 
for ischemic vascular and cardiovascular events regardless of study  drug relationship is 
presented in Table 6 -2.
These guidelines provide general principles and recommendations intended to support the 
investigator’s judgment and decisions about appropriate management of toxicity  in the 
individual patient.
However, for those toxicities detailed in Table 6-2, the following rules (as detailed in the bullet 
points below) must be stri ctly followed:
Any non
-hematological toxicity  Grade [ADDRESS_4819] be resolved within 28 day s to ≤ Grade 
[ADDRESS_4820] be disc ontinued from the study .
If Grade [ADDRESS_4821] be discontinued from the study .
In case of Grade [ADDRESS_4822] be 
consulted immediately .
In case of Grade [ADDRESS_4823] be discontinued from study .
In case of Grade [ADDRESS_4824] be 
consulted immedi ately .
In case of Grade [ADDRESS_4825] be discontinued from study .
In case of recurrent QTcF prolongation to > [ADDRESS_4826] be discontinued unles s the reason for QTcF prolongation can be corrected (such as 
discontinuing or replacing of QT -prolonging concomitant drugs)

[COMPANY_001] Confidential Page 36
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Table 6-2 Summary  of nilotinib dose reduction guid elines for study  drug -related 
non-hematologic toxicity  and for ischemic vascular and 
cardiovascular events regardless of study  drug relationship (adult 
patients)
Study  drug and dose Nilotinib 600 mg daily  (as 300 mg BID) or Nilotinib 800 mg daily  (as 400 m g 
BID)
General non -hematological toxicity
Grade 2
(persisting > 7 days with 
optimal supportive care)The dose of nilotinib may be reduced to [ADDRESS_4827] of the patient
≥ Grade 3 ● Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4828] be 
discontinued from the study.
●If Grade 4 toxicity recurs despi[INVESTIGATOR_5312] 400 mg QD
l→ discontinue from the study.
Serum hy pophosphatemia
Grade 2 -3 Continue nilotinib at 300 mg BID and start phosphate supplementation.
Grade 4 Hold study drug and consult [COMPANY_001].
Serum creatinine
Grade 2
> 1.[ADDRESS_4829] of the patient.
≥ Grade 3
≥ 3.[ADDRESS_4830]●Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4831] be 
discontinued from the study.
● If Grade 4 toxicity recurs despi[INVESTIGATOR_5312] 400 mg QD
l→ discontinue from the study.
Hepato -biliary [bilirubin, SGPT ( AST), SGOT (ALT)] 
Note : If hyperbilirubinemia is primarily due to the indirect bilirubin [with indirect bilirubin > direct bilirubin and 
direct bilirubin ≤ 1.[ADDRESS_4832] and ALT ≤ Grade 1, AST ≤ Grade 1, ALP ≤ Grade 1, and hemolysis has been ruled 
out as per institutional guidelines (e.g. by [CONTACT_5350])], nilotinib may be continued at the 
same dose, at the discretion of the investigator.
Grade [ADDRESS_4833] of the patient.
≥ Grade 3 ● Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4834] be 
discontinued from the study.
● If Grade 4 toxicity recurs despi[INVESTIGATOR_5312] 400 mg QD
l→ discontinue from the study.

[COMPANY_001] Confidential Page 37
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Study  drug and dose Nilotinib 600 mg daily  (as 300 mg BID) or Nilotinib 800 mg daily  (as 400 m g 
BID)
Combined elevations of AST or ALT and total bilirubin
For patients with normal 
baseline ALT and AST 
and total) bilirubin value:
AST or 
ALT >3.0xULN 
combined with 
direct or total 
bilirubin >2.[ADDRESS_4835] without 
evidence of 
cholestasis
OR (Note to study team: 
If supported by [CONTACT_5351])
For patients with 
elevated baselin e AST or 
ALT or total bilirubin 
value:
AST or ALT>2x 
baseline AND > 
3.[ADDRESS_4836] or ALT > 8.[ADDRESS_4837], 
combined with total 
bilirubin >2x baseline 
AND >2.0 x ULNMandatory : 
-Monitor for hemolysis. 
- If elevations of ALT and/or AST (>3.[ADDRESS_4838]) and tot al bilirubin (>2.[ADDRESS_4839]) 
without evidence of cholestasisd(ALKP < [ADDRESS_4840]) are observed 
simultaneously at the same visit: interrupt dose and monitor for hemolysis. If 
abnormality persists without evidence of hemolysis, permanently discontinue 
patient from study drug treatment.
Recommendation: If elevations of direct or total bilirubin precede the elevations of 
ALT and or AST, monitor for hemolysis. 
Repeat as soon as possible, preferably within [ADDRESS_4841] resolved to 
baseline or stabil ization over 4 weeks. 
Pancreatitis (with abdominal sy mptoms plus lipase elevation)
Grade 2 ●Hold study drug and perform abdominal CT with contrast to exclude pancreatic 
pathology.
●If CT is positive, continue to hold therapy and repeat CT, at investigator’s 
discretion.
●If CT is negative, re -start nilotinib at 400 mg QD after recovery to ≤ Grade 1 is 
seen.
●If recovery to ≤ Grade [ADDRESS_4842] be 
discontinued from the study.
●If toxicity recurs
l→ discontinue f rom the study.
Grade [ADDRESS_4843] be discontinued from study.
Elevated lipase without sy mptoms
≥ Grade 3 ●Hold study drug.
●Re-start nilotinib at 400 mg QD after recovery to ≤ Grade 2 is seen.
●If recovery to ≤ Grade [ADDRESS_4844] be 
discontinued from the study.
●If toxicity recurs without symptoms consider appropriate diagnostic procedures 
such as abdominal CT or ultrasound to exclude pancreatitis. Af ter recovery to ≤ 
Grade 2,
l→ continue dosing at 400 mg QD based on investigator’s discretion.

[COMPANY_001] Confidential Page 38
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Study  drug and dose Nilotinib 600 mg daily  (as 300 mg BID) or Nilotinib 800 mg daily  (as 400 m g 
BID)
Diarrhea
Note : Anti -diarrheal medication is recommended at the first sign of loose stools or overt diarrhea. If diarrhea 
cannot be controlled with optimal anti -diarrheal treatments, take the following actions:
≥ Grade 3 ● Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4845] be 
discont inued from the study.
Vomiting
Note : Antiemetic medication should be withheld until the patient experiences ≥ grade [ADDRESS_4846] 
be avoided. If nausea and vomiting cannot b e controlled with optimal antiemetic treatment take the following 
actions: 
≥ Grade 3 ● Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4847] be 
discontinued from the study.
Skin rash
Note : Institute symptomatic therapy as appropriate. If skin rash does not resolve with optimal treatments, take 
the following actions:
Grade 2 ●The dose of nilotinib may be reduced to [ADDRESS_4848] of the patient.
≥ Grade 3 ● Hold study drug and resume nilotinib at next lower dose level after recovery to 
≤ Grade 2 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4849] be 
discontinued from the study.
● If Grade 4 toxicity recurs despi[INVESTIGATOR_5312] 400 mg QD
l→ discontinue from the study.

[COMPANY_001] Confidential Page 39
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Study  drug and dose Nilotinib 600 mg daily  (as 300 mg BID) or Nilotinib 800 mg daily  (as 400 m g 
BID)
Cardiac QTc prolongation
QTcF > 480 msec ●Hold study drug when an ECG with a QTcF > 480 msec. 
● In addition to the procedures below, t he investigator should follow their local 
standards of practice and treatment guidelines for treating prolonged QT intervals. 
●Perform an analysis of serum potassium and magnesium, and if below lower 
limit of normal, correct with supplements to within normal limits.
●Concomitant medication usage must be reviewed for their potential to inhibit 
CYP3A4 and/or to prolong the QT-interval.
●Perform a repeat ECG within one hour of the first QTcF of > 480 msec.
●If QTcF remains > [ADDRESS_4850] 
once a day until the QTcF returns to < 480 msec.
●Study drug may be restarted, at same dose, if reason for elevation of QTcF is 
identified and corrected so that QTcF returns to < 450 msec and to within 20 msec 
of baseline within 2 weeks.
●ECGs must be repeated 7 days after dose re -start for all patients who had 
therapy held due to QTcF > 480 msec.
●If the QTcF is repeated and is more than 20 msec greater than baseli ne or 
between 450 msec and 480 msec, the dose of study drug should be reduced to 
400 mg QD.
● If QTcF of > 480 msec recurs, the patient is to be discontinued from the study.
● The investigator should contact [CONTACT_5352] a 
patient with QTcF prolongation should be maintained on study.
●Note : QTcB can be used in centers that do not have the ability to automatically 
measure QTcF for QTc prolongation. In patients with a heart rate lower than 60 
per minute decisions are always based on QTcF because QTcB underestimates 
QT prolongation at heart rates below 60 per minute. 
Study drug and dose Nilotinib 600 mg daily (as 300 mg BID)
Ischemic vascular or cardiovascular events
Grade 2* ●Hold study drug and refer patient for assessment by a vascular or 
cardiovascular specialist.
● Resume nilotinib at next lower dose level after recovery to ≤ Grade 1 is seen
l→ 400 mg QD.
●If another recurrence
l→ discontinue from the study.
●If recovery to ≤ Grade [ADDRESS_4851] be 
discontinued from the study.
Grade 3* or 4* ●Hold study drug and refer patient for assessment by a vascular or 
cardiovascular specialist. Consideration should be given for discontinuation from 
the study. The patient must be discontinued from the study if recovery to ≤ Grade 
2 is greater than 28 days.
* Patient should be assessed for potential risk factors for the event including causality secondary to CML 
therapy.
Cardiac “other”
Grade 2 or Grade 3 ●Hold study drug and re sume nilotinib at next lower dose level after recovery to 
≤ Grade 1 is seen
l→ 400 mg QD.
●If recovery to ≤ Grade [ADDRESS_4852] be 
discontinued from the study.
● If Grade 3 toxicity recurs despi[INVESTIGATOR_5312] 400 mg QD
l→ discontinue from the study.
Grade [ADDRESS_4853] be discontinued from the study.

[COMPANY_001] Confidential Page 40
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
[IP_ADDRESS] Dose reduction guidelines for study  drug -related hematological 
toxicity
A summary  of dose reduction guidelines for ≥ Grade 3 study  drug-related hematological 
toxicity  for 300 mg BID or 400 mg BID dose is presented in Table 6-3. No dose adjustments 
should be made for Grade 1 or 2 hematologic toxicities. These guidelines provide some gene
ral 
principles as well as recommendations which are intended to support the investigator’s 
judgment and decision about the appropriate management of toxicity  in the individual patient. 
However , if a hematological toxicity  does not resolve to ≤ Grade [ADDRESS_4854] be consulted.
Table 6-3 Summary  of dose reduction guidelines for study drug -related 
hematological toxicity
Study  drug and dose Nilotinib 600 mg daily  (as 300 mg BID) or Nilotinib 800 mg daily  (as 400 mg 
BID)
≥ Grade 3 Hold therapy and resume nilotinib at the full dose after recovery to ≤ Grade 2, if 
recovery occurs within 14 days
If ≥ Grade 3 toxicity persists for 15-28 days or recurs, hold therapy and resume at 
next lower dose level after recovery to ≤ Grade 2:
l→400 mg QD
If recovery to ≤ Grade 2 is greater than 28 days, consult [COMPANY_001].
If another recurr ence is seen
l→discontinue.
Note: Dose of study drug need not be reduced or interrupted for hematological toxicity of Grade [ADDRESS_4855] be 
discontinued from the study .
6.3.2 Dose reduction guidelines for study  drug -related toxicity  for pediat ric 
patients
A summary  of dose reduction guidelines for study  drug-related toxicity  for 230 mg/m2BID 
dosage is presented in Table 6 -4.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4856] toxicity
NCI CTCAE grade During therapy
No toxicity Maintain dose level
Hematological -includes thrombocy topenia, neutropenia, leukopenia, and/or anemia
Grade 1 -2 Hematological No dose interruptions or reductions
Grade 3 -4 Hematological
●Note (1): No dose reductions will be performed for grade 3/4 
anemia. If the patient develops anemia, s/he may be 
transfused at the discretion of the Investigator.
●Note (2): Use of G -CSF and GM -CSF may be initiated with 
recurrent Grade 3 neutropenia after consulting with the 
sponsor. Refer to Section [IP_ADDRESS] for more details.First Occurrence :
1.Hold nilotinib until recovery to grade ≤ 1.
● If recovery occurs within [ADDRESS_4857] day of dosing, resume nilotinib at the same 
daily dose.
● If recovery occurs more than 2 weeks but ≤ [ADDRESS_4858] day of dosing, resume 
nilotinib at:
2.230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or c ontact [COMPANY_001] if 
prior dose was 230 mg/m2once daily.
Second Occurrence :
1.Hold nilotinib until recovery to grade ≤1.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or contact [CONTACT_5353] 230 mg/m2once daily.
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months
Hepato -biliary
Total bilirubin ≥ Grade 2
Note: If hyperbilirubinemia is due to the indirect component 
only, and hemolysis as the etiology has been ruled out as per 
institutional guidelines (e.g., review of peripheral blood smear 
and haptoglobin determination), , nilotinib may be continued at 
the same dose at the discretion of the Investigator.First Occurrence:
1.Hold nilotinib until return to ≤ grade 1.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or discontinue patient 
from the study if prior dose was 230 mg/m2once daily.
Second Occurrence:
Stop nilotinib and contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months

[COMPANY_001] Confidential Page 42
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4859] toxicity
NCI CTCAE grade During therapy
No toxicity Maintain dose level
≥Grade [ADDRESS_4860] (SGOT) or ALT (SGPT) First Occurrence:
1.Hold nilotinib until return to ≤ grade 1 (or baseline if disease rel ated).
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or discontinue patient 
from the study if prior dose was 230 mg/m2once daily.
Second Occurrence:
Stop nilotinib and contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months
Amylase and/or Lipase without sy mptoms ≥ Grade [ADDRESS_4861] Occurrence:
1.Hold nilotinib until return to ≤ grade 1.
2.Abdominal CT with contrast to exclude pancreatic pathology.
3.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or contact [CONTACT_5353] 230 mg/m2once daily.
Second Occurrence:
Continue dosing, if asymptomatic and CT negative, at Investigator’s discretion.
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months
Pancreatitis ≥ Grade 2 (abdominal symptoms with amylase 
and/or lipase elevation)First Occurrence:
1.Hold nilotinib until return to ≤ grade [ADDRESS_4862] resolved, with continued 
monitoring for recurrent symptoms at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or discontinue patient 
from the study if prior dose was 230 mg/m2once daily.
Second Occurrence:
Stop nilotinib and discontinue patient from the study treatment.
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sp onsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months

[COMPANY_001] Confidential Page 43
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4863] toxicity
NCI CTCAE grade During therapy
No toxicity Maintain dose level
Cardiac –QTc
ECGs with a QTcF > 480 ms 1.In addition to the procedures below, the investigator should follow their local standards of 
practice and treatment guidelines for treating prolonged QT intervals. 
2.Hold nilotinib when an ECG with a QTcF > 480 ms by [CONTACT_5354] e site.
3.Call the study’s central ECG review laboratory immediately, request a manual read of ECG result 
and notify [COMPANY_001].
4.Perform an analysis of serum potassium and magnesium, and if below lower limit of normal, 
correct with supplements to within normal limits. Concomitant medication usage must be reviewed.
5.Perform a repeat ECG within one hour of the first QTcF of > [ADDRESS_4864] to the study’s 
central ECG review laboratory for a manual reading.
6.If QTcF remains > [ADDRESS_4865] once a day until the 
QTcF returns to < 480 ms.
7.Nilotinib may be restarted at the same dose, if reason for elevation of QTcF is identified, 
corrected and QTcF returns to < 450 ms and to within 20 ms of baseline within 2 weeks. If QTcF is 
repeated and is more than 20 ms greater than baseline or between 450 ms and 480 ms the dose of 
nilotinib is to be reduced by [CONTACT_2016]:
● 230 mg/m2once daily if prior dose was 230 mg/m2twice daily OR
● discontinue patient from treatment if prior dose was 230 mg/m2once daily.
With resumption of nilotinib at the same or at a reduced dose after interruption of therapy due to 
QTcF > [ADDRESS_4866] be obtained on days 2, 3, and 8.
8.If QTcF > [ADDRESS_4867] all ECGs to the study’s central ECG review laboratory. Any ECG with a QTcF >[ADDRESS_4868] be forwarded by [CONTACT_5355]’s 
central ECG review laboratory.
No dose re -escalation is allow ed after dose reduction due to QTcF prolongation suspected to be 
related to nilotinib

[COMPANY_001] Confidential Page 44
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4869] toxicity
NCI CTCAE grade During therapy
No toxicity Maintain dose level
Ischemic cardiovascular events
Grade 2* First Occurrence:
1.Hold nilotinib and refer patient for assessment by a vascular or cardiovascular specialist.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily after recovery to ≤ Grade 
1 is seen
Second Occurrence:
Stop nilotinib and contact [CONTACT_5356] ≤ Grade [ADDRESS_4870] be disconti nued from the study.
Grade 3* or 4* 1.Hold therapy and refer patient for assessment by a vascular or cardiovascular specialist.
2.Consideration should be given for discontinuation from the study. 
3.The patient must be discontinued from the study if re covery to ≤ Grade 2 takes more than 28 
days
* Patient should be assessed for potential risk factors for the event including causality secondary to CML therapy
Gastrointestinal
Diarrhea
Grade [ADDRESS_4871] Occurrence:
1.Institute symptomatic therapy as appropriate.
2.If diarrhea cannot be controlled with optimal anti-diarrheal treatments, hold nilotinib until resolved 
to ≤ grade 1, then resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or discontinue patient 
from the treatment if prior dose was 230 mg/m2once daily.
Anti-diarrheal medication is recommended at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or 
overt diarrhea.
Second Occurrence:
If diarrhea cannot be contro lled with optimal anti -diarrheal treatments, stop nilotinib and contact 
[CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The l ength of dose discontinuation should not exceed more than 2 months

[COMPANY_001] Confidential Page 45
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4872] Occurrence:
1.Institute symptomatic therapy as appropriate.
2.If vomiting or nausea cannot be controlled with optimal antiemetic treatments, hold nilotinib un til 
resolved to ≤ grade 1 then resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily or discontinue patient 
from the treatment if prior dose was 230 mg/m2once daily.
Second Occurrence:
If vomiting or nausea cannot b e controlled with optimal antiemetic treatments, stop nilotinib and 
contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than [ADDRESS_4873] Occurrence :
1.Institute symptomatic therapy as appropriate.
2.If skin rash does not resolve with optimal treatments, hold nilotinib until resolved to ≤ grade 1, 
then resume nilotinib at the same daily dose.
Second Occurrence :
1.Hold nilotinib instituting symptomatic therapy until recovery to grade ≤1.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily.
If further recurrence, stop nilotinib and contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than [ADDRESS_4874] Occurrence :
1.Hold nilotinib instituting symptomatic therapy as appropriate, until recovery to grade ≤ 1.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily.
Second Occurrence :
Stop nilotinib and contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinu ation.
The length of dose discontinuation should not exceed more than 2 months

[COMPANY_001] Confidential Page 46
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A [ADDRESS_4875] Occurrence :
1.Hold nilotinib instituting symptomatic therapy as appropriate, until recovery to grade ≤ 1.
2.Resume nilotinib at:
230 mg/m2once daily in AM or PM if prior dose was 230 mg/m2twice daily.
Second Occurrence :
Stop nilotinib and contact [CONTACT_5343].
If recovery to ≤ Grade 1 greater than 28 days, investigator will consult sponsor to define appropriate 
length of dosing reduction/interruption prior to discontinuation.
The length of dose discontinuation should not exceed more than 2 months

[COMPANY_001] Confidential Page 47
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Every  attempt to re-escalate the dose of study  treatment to the initial dose level should be made. 
This applies to dose reductions due to both hematological and non-hematological toxicities with 
the exception of dose reductions due to prolongation of 
QT interval. The dose should be re-
escalated if the following criteria are met at least one month after dose reduction:
All ≥ Grade [ADDRESS_4876] resolved to ≤ Grade 1
All ≥ Grade [ADDRESS_4877] resolved to ≤ Grade 1
Or alternatively , all ≥ Grade [ADDRESS_4878] 
resolved to ≤ Grade [ADDRESS_4879] be recorded on the “Dosage Administration Record” CRF.
6.3.[ADDRESS_4880]  of some statins (HMG- CoA reductase inhibitors). A list of 
these drugs is listed in Appendix [ADDRESS_4881]. For further recommendations regarding the management of 
ischemic vascular or cardiovascular -related events refer to Table 6-2and Table 6-4and the 
current nilotinib [I nvestigator’s Brochure].

[COMPANY_001] Confidential Page 48
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
6.3.[ADDRESS_4882] positive for hepatitis B 
virus during nilotinib treatment. Carrie rs of hepatitis B virus who require treatment with 
nilotinib should be closely  monitored for signs and symptoms of active hepatitis B infection 
throughout therap y and for several months following termination of therapy.
6.3.8 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal ALT and AST and TBIL value at baseline: AST or AL T > 3.[ADDRESS_4883] combined with TBIL > 2.0 x UL N
For patients wit h elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.[ADDRESS_4884]] OR [AST or ALT > 8.[ADDRESS_4885]], combined with [TBIL > 2 x 
baseline AND > 2.[ADDRESS_4886]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_5357], defined 
as ALP elevation > 2.[ADDRESS_4887] with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  [CONTACT_5358], using multiples of the U LN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discon tinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT )/INR and alkaline phosphatase.
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-
existing liver 
conditions or risk factors, should be collected.
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. b iliary  
tract) may  be warranted.
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK anal ysis is 
performed in the stud y.
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultatio n with specialist/hepatologist.

[COMPANY_001] Confidential Page 49
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the term 
“potential drug-induced liver injury ”. Allevents should be followed up with the outcome clearl y 
documented.
6.4 Concomitant medications
6.4.1 Prohibited concomitant therapy
In general, concomitant medications/therapi[INVESTIGATOR_5313].
Avoid the concomit ant use of strong CYP3A4 inhibitors and inducers (refer toAppendix Iin
Section 14.1). Should treatment with strong CYP3A4 inhibitors be required, it is recommended 
that therap y with nilotinib be interrupted if possible. Close monitoring of prolongation of the 
QT interval is indicated for patients who cannot avoid strong CYP3A4 inhibitors. For further 
details refer to the current nilotinib [I nvestiga tor’s Brochure].
Cytochrome P450 3A 4 substrates:
Nilotinib is a moderate CYP3A4 inhibitor in vivo. Because of the potential risk for drug-drug 
interactions, the systemic exposure of other drugs known to be sensitive substrates of CYP3A4 
and also to have a narrow therapeutic index should be used with caution. A list of these drugs 
is listed in Appendix I inSection 14.1.
Every effort should be made NOT to administer strong CYP3A4 inhibitors CYP3A4 
inhibitors may  decrease the metabolism of nilotinib and thereb y increase serum concentrations 
and increase exposure. If administration of a strong CYP3A4 inhibitor cannot be avoided during 
the study and cannot be switched to an alternative therap y,study  treatment must be STOPPED. 
Furthermore, increased awareness should be exercised when administering moderate inhibitors 
and/or multiple weak inhibitors. A list of these medications and inhibitor classifications can be 
found in 
Appendix 1 ; however, this list may not be comprehensive.
Every  effort should be made NOT to administer strong CYP3A4 inducers however, if
administration of a CYP3A4 inducer cannot be avoided during the study , temporary 
discontinuation of study  treatment is NOT required. A list of these medications and inducer 
classifications can be found in Appendix [ADDRESS_4888] may  not be comprehensive.
Antacid drugs:
Nilotinib has a pH -dependent solubility ; therefore, in order not to impact nilotinib 
pharmacokinetics, administration of the following antacid drugs (if necessary) should be as 
follows:
H2 blocker (e.g. famotidine) may  be administered approximately  10 hours before o r 
approximately  2 hours after the dose of nilotinib,
Antacids (e.g. magnesium hy droxide, simethicone) may  be administered approximately  2 
hours before or approximately  2 hours after the dose of nilotinib

[COMPANY_001] Confidential Page 50
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Drug with “Known risk of Torsades do Pointes,” “Poss ible risk of Torsades de 
Pointes,” or “Conditional risk of Torsades de Pointes” :
Every  effort should be made to avoid co-administering the study  drug and drugs with a “Known 
risk of Torsades do Pointes,” “Possible risk of Torsades de Pointes,” or “Conditio nal risk of 
Torsades de Pointes” (as per https://credible meds.org/) during the course of the study :
If concomitant administration of drugs with a “Known risk of Torsades de Pointes” is 
required and cannot be avoided, study  drug must be interrupted. If, bas ed on the 
investigator assessment and clinical need, stud y treatment is resumed, close ECG 
monitoring is advised.
If during the course of the study, concomitant administration of a drug with “Possible 
risk” or “Conditional risk of Torsades de Pointes” is required, based on the investigator 
assessment and clinical need, stud y drug may be continued under close ECG monitoring 
to ensure patient safet y.
A list of drugs associated with QT prolongation and/or Torsades de Pointes is available online
at 
https://crediblemeds.org/   
All patients must avoid grapefruit, star fruit, pomegranate and Seville oranges during the study.  
The juices and products containing these fruits must also be avoided.
Cardiac Monitoring .
Cardiac monitoring is required upon re-initiation of nilotinib therapy at any point. An 
ECG must be obtained before the treatment re -initiation, 4 weeks after reinitiation and annuall y 
thereafter during nilotinib therap y. A minimum washout period of 72 hours or longer is 
required (depending on the half-life of the CYP3A4 inhibitor or QT interval prolonging 
agent) prior to study drug re -initiation. Documentation will be kept in source document.
6.4.2 Use of Bisphosphonates (or other concomitant agents)
Not applicable
6.[ADDRESS_4889] Number (Subject 
No.), that is assigned when 
the patient is first enrolled in the roll- over stud y and is retained as the primary identifier for the 
patient throughout his/h er entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential patient 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the patient is assigned to the next sequential Subject 
No. available to the investigator through the Oracle Clinical RDC interface (OCRDC). 
Additionally  an eCRF will be completed that identifies the patie nt by [CONTACT_5360], site/center and subject number.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
6.5.[ADDRESS_4890] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Dosage Administration Record eCRF.
Table 6-5 Preparat ion and dispensing
Study  treatments Dispensing Preparation
Nilotinib *Hard Gelatin Capsules (150mg and 200mg, additional strengths 
can be provided if specified in the parent protocol) including 
instructions for administration will be dispensed by [CONTACT_5362].
Patients will be provided with an adequate supply of study treatment 
for self -administration at home until at least their next scheduled 
annual (+/ -3 months) study visit.Not applicable
* Different formulations and strengths can be used once they are approved and marketed.
6.6.[ADDRESS_4891] [Investigator Brochure] for nilotinib dosing instructions and storage 
conditions.

[COMPANY_001] Confidential Page 52
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Table 6-6 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
Nilotinib Capsules in bottles* As per local requirements
* For centrally supplied medication. If nilotinib is sourced and labeled in -country/locally, the locally-approved 
form, packaging and labeling of nilotinib will be used.
6.6.[ADDRESS_4892] access. Upon receipt, the nilotinib should be stored according to the 
instructions specified on the drug labels and in the current [Investigator’s Brochure].
Table 6-[ADDRESS_4893] information
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug account ability  log. Drug accountability  will be noted by [CONTACT_5364]. Patients will be asked to return all 
unused study  treatment and packaging on a regular basis, at the end of the study  or at the time 
of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.6.[ADDRESS_4894] part y, as appropriate.

[COMPANY_001] Confidential Page 53
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. A visit window of +/ -
[ADDRESS_4895] be supported in the patient’s source documentation.
The table indicates which assessments produce data to be entered into the database (D) or 
remain in source documents only  (S) (“Category ” column).
Hepatitis B testing will be performed once and only  once, at the next po ssible visit.

[COMPANY_001] Confidential Page 54
Amended Protocol Version 0 5 (Clean ) Protocol No. CAMN107A2409
Table 7-1 Visit evaluation schedule
CategoryProtocol 
Reference 
Section EnrollmentQuarterly  (12 weeks +/- 1 week) visits during 
treatment phaseEnd of study  
treatment 
(EoT)Safety  
Follow -
up/End of 
study
Visit Number 1 Visit 2,3,4 etc. 777 778
Informed consent D 7.1.2 x
Patients’ previous study, site and subject 
numberD [IP_ADDRESS] x
Demography D [IP_ADDRESS] x
Relevant medical history/current medical 
conditionsD [IP_ADDRESS]
Inclusion/exclusion criteria D 5.2/5.3. x
Nilotinib dosing D 6.1. x X
Pregnancy testing D,S 7.1.4 x Monthly (home) x
Hepatitis screen D [IP_ADDRESS] to be performed once and only o nce, at the next 
possible visit
Confirmation of Clinical Benefit from 
Study Treatment D 6.1.5 x X x
Adverse events and s erious a dverse 
events D 8.1/ 8.2. Continuous x
End of study treatment D 7.1.5 x
Study Evaluation Completion D 7.1.5 x

[COMPANY_001] Confidential Page 55
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
7.1.1 Molecular pre -screening
Not applicable.
7.1.2 Screening
At the enrollment visit the patient will need to complete a written informed consent. There will 
be no screening period for this study . Once consented, patients will be evaluated for eligibility 
via the inclusion and exclusion criteria.
[IP_ADDRESS] Eligibility  screeni ng
Not applicable.
[IP_ADDRESS] Information to be collected on screening failures
Not applicable.
[IP_ADDRESS] Patient demographics and other baseline characteristics
For patients that are eligible to participate in this roll-over study , the patients’ gender, date of 
birth and previous study , site/center and subject number and relevant medical history  will be 
collected.
7.1.[ADDRESS_4896] dose that was given in the parent 
nilotinib study . A 3 month supply  of nilotinib will be dispensed to the patient/or as per local 
practice.
Patients must return to the study  center on a quarterly  basis (12 weeks +/ -1 week), for 
resupply  of study  medication at which time limited drug dispensing and adverse event
information will be collecte d.At every  quarterl y visit (12 weeks +/ -1 week) , the investigator 
is required to confirm that the patient continues to have clinical benefit and may  continue 
receiving stud y treatment. At this time the dose of nilotinib is based on the investigator’s 
judgment. The stud y is expected to remain open for 10years from the First Patient First Visit 
in this clinical study , until study  treatment becomes commerciall y available and is reimbursed 
in the respective indication or until such time that enrolled patients no longer need treatment 
with nilotinib, whichever comes earlier. Should nilotinib not be commercially  available to 
patients at end of stud y due to local regulations, [COMPANY_001] will make every effort to ensure that 
patients benefiting from treatmen t continue to have access to nilotinib without interruption of 
treatment in accordance with local regulation.
7.1.[ADDRESS_4897] negative for a pregnancy  (either with serum testing if 
routinely /locall y available or urine pregnancy  test) b efore enrolling into the study .

[COMPANY_001] Confidential Page 56
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Women of child -bearing potential, defined as all women physiologically  capable of becoming 
pregnant, unless they are using highl y effective methods of contraception during the study and 
for 30 day s after the final dose of nilotinib.
Highl y effective contraception is defined as either:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -
ovulation methods) 
and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n case of 
oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by [CONTACT_104].
Male sterilization (at least 6 month s prior to enrolling). For female patients on the study  
the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contraception or placement of an 
intrauterine device (IUD) or intraute rine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
If patient has tested negative at the end of study  on the parent study , no pregnancy  testing is 
required if enrollment into this study  is carried out on the same day or within few days 
(maximum 5 day s) from each other.
Female patients of child bearing potential are required to perform monthly  home urine 
pregnancy  tests and comple te a simple diary  with the dates and the outcome of the home urinary 
test while on study  treatment and during safet y follow -up (30 day s after the final dose of study 
medication).
A pregnancy  test (either with serum testing if routinely /locally  available orurine pregnancy  test) 
on female patients of child bearing potential is required at the final stud y visit.
Any positive results will be recorded in the database and followed up as per Section 8.4.
(Note: In terms o f pregnancy  prevention in a pediatric population, the detailed guidance in the 
parent protocol could be followed.)
7.1.5 Discontinuation of study treatment
Patients will continue to be treated until they  are no longer benefiting from nilotinib treatment, 
develop unacceptable toxicities, withdraw consent, are non-compliant to the protocol, the 
investigator feels it is no longer in the patient’s best interest to continue nilotinib therapy ,the 
patient 
dies, [ADDRESS_4898] access to nilotinib without interruption of treatment in accordance with local 
regulation. At the time the patient discontinues study  treatment, a visit should be scheduled as 
soon as possible, at which time the assessments listed for the End of Treatment (EOT) visit will 
be performed. End of Treatment information will be completed in the eCRF giving the date and 

[COMPANY_001] Confidential Page 57
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
reason for stoppi[INVESTIGATOR_5314] (Section [IP_ADDRESS]), e.g.,physician decision, disease 
progression, cause of death, lost to follow -up, withdrawal of consent, etc.
At a minimum, all patients who discontinue study  treatment, including those w
ho refuse to 
return for a final visit, will be contact[CONTACT_5365] a safet y evaluation during the [ADDRESS_4899] 
determine the primary  reason for a patient’s withdrawal from the study  and record this 
information on the appropriate eCRF page.
A pa tient will reach the end of study  when nilotinib treatment is permanently discontinued and 
there will be nofurther follow -up study  visits.
[IP_ADDRESS] Criteria for premature patient withdrawal
Patients may  voluntarily  withdraw from the study  or be dropped from it at the discretion of the 
investigator at an y time.
Patients may  be withdrawn from the study  if an y of the following occur:
1.Death* ,
2.Lost to follow -up,
3.Staying in the study  would be harmful ,
4.Adverse event,
5.Disease progression,
6.Patient/guardian decision*
,
7.Physician decision ,
8.Patient is non -compliant to protocol requirements ,
9. Protocol deviation,
10.Patient becomes pregnant*,
11.Study  terminated by  [CONTACT_3211] .
*Note: Patients who are pregnant, withdrawn consent or have died must be withdrawn from the 
study .
[IP_ADDRESS] Replacemen t policy
Not applicable.
7.1.6 Withdrawal of consent
Patients may voluntaril y withdraw consent toparticipate inthestudy foranyreason atany 
time.Withdrawal of consent occurs only when apatient

[COMPANY_001] Confidential Page 58
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g.,telephone, e-mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been c ollected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366] -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
7.1.[ADDRESS_4900] the patient to inquire about 
any adverse events or serious adverse events ( SAEs) observed during this period. This could be 
done via a phone contact. Following this there are nofurther follow -up study  visits
Patients lost to follow up should be recor ded as such on the appropriate eCRF. For patients who 
are lost to follow -up, the investigator should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc.
Data collected should be added to the Adverse Events eCRF.
7.1.[ADDRESS_4901] to fo llow- up
Forpatie ntswhose status is unclear because they fail toappear forstudy  visits without stating 
anintention towithdraw consent, theinvestigator should show "due diligence" by[CONTACT_5368], family orfamily physician asa
greed in theinfor medconsent andby[CONTACT_5369], e.g. dates oftelephone calls, 
registered letters,etc.Apatie ntsho uldnot be considered losttofollow -upuntil duediligence 
hasbeen completed. Patients losttofollow upshould berecorded assuch ontheappropriate 
Disposition CRF.
7.[ADDRESS_4902] 
clinical benefit and may  continue receiving stud y treatment.

[COMPANY_001] Confidential Page 59
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by [CONTACT_5370]. For details on AE 
collection and reporting, refer to Section 8.
[IP_ADDRESS] Hepatitis B testing
Patients will be tested once for the following hepatitis B serologic markers: hepatitis B surface 
antigen (HBs Ag) and antibodies to hepatitis B core antigen (HBc Ab / anti HBc).
Patients currently  on nilotinib should have testing performed at the next possible visit in order 
to identify  chronic carriers.
7.2.3 Pharmacokinetics
Not applicable.
[IP_ADDRESS] Analytical method
Not applicable.
[IP_ADDRESS] Additional biomarker assessment s
Not applicable.
7.2.4 Resource utilization
Not applicable.
7.2.5 Patient reported outcomes
Not applicable.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinica l signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Any ongoing adverse events from the parent study  will be captured as medical history  in the 
roll-over database . Any AE that begins (or worsens) after signing of the informed consent for 
the roll-over and during the 30-day (or 28-day) safet y follow up period defined in the parent 
protocol should be repor ted in both clinical databases.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Adverse event monitoring should be continued for at least [ADDRESS_4903] dose of 
study  treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenev er possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed according to the current version of Common Terminology 
Criteria for Adverse Events (CTCAE).
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life -threatening, corresponding to Grades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in thisstudy; rather, information about deaths will be collected through the EOT 
eCRF page.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and ateach visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2. Its duration (start and end dates)
3.Its relationship to the study  treatment (reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  orinvestigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Wheth er it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
If the event worsens the event should be reported a second time in the CRF noting the start date 
when the event worsens in toxicity . For grade 3 and 4 adverse events onl y, if improvement to a 
lower grade is determined a new entry  for this event should be reported in the CRF noting the 
start date when the event improved from h aving been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be perm anent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (includi
ng fatal outcomes), if documented by [CONTACT_5371] (for example, as per RECI ST criteria for solid tumors or as per Cheson's guidelines for 
hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
be reported as per usual guidelines used for such events with proper attribution regarding 
relate dness to the drug.
8.1.[ADDRESS_4904] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adve rse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 events (severe) as per CTCAE does not automatically 
indicat e a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by [CONTACT_108], be an adverse event 
and must be reported as such.
8.1.[ADDRESS_4905] (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by  [CONTACT_5372]. Such events may require further investigation in order to characterize and 
understand them.
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. AESIs are discussed in detail in the 
[Investigator Brochure].
Ischemic vascular and ischemic cardiovascular events include (but are not limited to) the events 
listed below. Patients should be educated on the clinical symptoms of such events to ensure 
accurate reporting to the Investigator.
Ischemic Heart Disease (IHD): angina pectoris, coronary  artery  disease, acute my ocardial 
infarction and coronary  artery  stenosis
Ischemic Cerebrovascular Events (ICVE) : ischemic cerebrovascular accident
, and 
transient ischemic attack
Peripheral Artery  Occlusive Disease (PAOD): intermittent claudication, arterial stenosis 
of a limb
If patients experience ischemic vascular or ischemic cardiovascular events (i.e. ischemic,
cardiac, cerebrovascular or peripheral artery -related), carefully  consider guidance provided in 
the current nilotinib [I nvestigator’s Brochure].

[COMPANY_001] Confidential Page 62
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
The Investigator should ensure that the patient is assessed by a vascular or cardiovascular 
specialist.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e ., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_3850],
Note that hospi[INVESTIGATOR_5315] t he following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unre lated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency  outpatient basis that doe s not result in hospi[INVESTIGATOR_5317] y of the definitions of a SAE given above 
is not a serious adverse event
8.2.[ADDRESS_4906] be reported to [COMPANY_001] within 24 hours of learning of its occurrence.
Any SAE that begins or worsens after signing of the informed consent for theroll-over and 
during the 30 -day (or 28 -day) safety  follow up period defined in the parent protocol should be 
reported as an adverse event in both clinical databases; however, only one SAE report will be 
sent to [COMPANY_001].
Any SAE that begins or worsens dur ing the 30- day (or 28 -day) safety  follow up period 
specified in the parent study  should have an SAE report submitted to [COMPANY_001] with th e 
parent protocol stud y number.
Any SAE that begins or worsens after the 30- day (or 28- day) safety  follow up period 
specified in the parent study  should have an SAE report submitted to [COMPANY_001] with the 
roll-over protocol stud y number.
Any additional information for the SAE including complications, progression of the initial SAE, 
and recurrent epi[INVESTIGATOR_5318] f ollow -up to the original epi[INVESTIGATOR_5319] 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separatel y as a new event.
It is important to use the right SAE form with the correct protocol number for these two 
scenarios, to avoid confusion in SAE processing. For a patient alread y on the roll -over protocol 
but follow up information is reported for the previous SAEs in the parent protocol, it must be 
clearl y labeled that this is for the parent protocol number.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to [COMPANY_001] if the investigator suspects a causal relatio nship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must asses s and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within [ADDRESS_4907] as the original SAE Report .Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated and whether the patient 
continued or withdrew from study  participation.
If the SAE is not previously  documented in the [Investigator’s Brochure ]or Package Insert 
(new occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology 
[COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) departm ent associate may urgently  require 
further information from the investigator for Health Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in partic ipating countries.
8.[ADDRESS_4908] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_623] (DS&E). Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 

[COMPANY_001] Confidential Page 64
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
possible relationship to the study  treatment any pregnancy  outcome. Any SAE experienced 
during pregnancy  must be reported on the SAE Report Form.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided nilotinib 
[Investigator Brochure]. Additional safety  information collected between [Investigator 
Brochure] updates will be communicated in the form of I Ns. This information will be included 
in the patient informed consent and should be discussed with the patient during the study  as 
needed.
8.[ADDRESS_4909] of the following:
What protected health in formation (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords , made available only to authorized personnel who have 
completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol andeCRFs with the investigators and 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. Al l information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additi onal checks of the consistency  of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to [ADDRESS_4910] been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_5321], accurate, and that entry  and updates are performed in a timely  manner.
9.4 Database management and quality  control
For studies using eCRFs, [COMPANY_001] personnel (or designated CRO) will review the data entered 
by [CONTACT_5375] . Electronic data queries stating the nature 
of the problem and requesting clarification will be created for discrepancies and missing values 
and sent to the investigational site via the EDC system. Designated investigator site staff is
required to respond promptly  to queries and to make any  necessary  changes to the data.
At the conclusion of the study , the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and made available for data analysis. 
Authorization is required prior to making any  database changes to locked data, by [CONTACT_5376].
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_5322].

[COMPANY_001] Confidential Page 66
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
[ADDRESS_4911] one dose of study  medication after 
enrolling into the roll -over protocol.
10.1.3 Dose -determining analy sis set
Not applicable.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data characteristics will be summarized descriptivel y for the 
Safety  Set.
10.3 Treatments (study  treatm ent, compliance)
Dose administration data will be summarized using the Safet y Set.
10.4 Primary  objective
The primary  objective is to evaluate long term safet y as assessed by [CONTACT_5377]/SAEs.
10.4.1 Variable
See Section 10.5.3.
10.4.2 Statistical hy pothesis, model, and method of analy sis
No hy pothesis will be tested.
10.4.3 Handling of missing values/censoring/discontinuations
Not applicable.
10.4.4 Supportive analy ses
No supportive 
analysis will be performed.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable.
10.5.2 Other secondary  efficacy  objectives
The secondary  objective of the study  was to evaluate clinical benefit as assessed by [CONTACT_1275]. Proportion of patients with cli nical benefit as assessed by  [CONTACT_5378] .

[COMPANY_001] Confidential Page 68
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
10.5.3 Safety  objectives
The assessment of safet y will be based mainly  on the frequency  of AEs and SAEs.
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_5323]:
1. on- treatment period: from day  of first dose of study  medication to [ADDRESS_4912]-treatment period: starting at day  30+[ADDRESS_4913] dose of study  medication.
[IP_ADDRESS] Adverse events (A Es)
Summary  tables of adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the post-treatment periods) will be listed and those collected during the 
post treatment period are to 
be flagged.
The incidence of treatment emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_5379]/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, relation to study  treatment.
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by [CONTACT_5380] b y type of adverse event.
[IP_ADDRESS] Other safety  data
Not applicable.
[IP_ADDRESS] Tolerability
Not applicable.
10.6 Interim analy sis
Not applicable.
10.7 Sample size calculation
Not applicable.
10.8 Power for analy sis of key
 secondary  variables
Not applicable.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical princ iples laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study  in 
accordance with these documents and all of the instru ctions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities a s required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IE C/REB -approved informed consent
Informed consent must be obtained before conducting any stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be c aptured in their CRFs.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Additional consent form
Not applicable.
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions spe cified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.4.

[COMPANY_001] Confidential Page 70
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publi
cly accessible database of clinical study  results.
11.[ADDRESS_4914] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GC P, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a [COMPANY_001] -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examin e (and when required by  [CONTACT_1289], to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory  notes, memo randa, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supe rvision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must beexplained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  [CONTACT_5382]. The investigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the comple tion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

[COMPANY_001] Confidential Page 71
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
11.[ADDRESS_4915] ensure anon ymity of the patients; patients must not be identified by [CONTACT_5384]. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_4916] be 
considered a protocol amendmen t, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.[ADDRESS_4917] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviati on from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safet y measures 
within 3 day s) but not later th an 10 working day s.

[COMPANY_001] Confidential Page 72
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
13 References (available upon request)
Bartram CR, de Klein A, Hagemeijer A, et al (1983) Translocation of c -ab1 oncogene 
correlates with the presence of a Philadelphia chromosome in chronic my elocy tic leukaemi a. 
Nature 306(5940):277 -80.
Bertucci F, et al (2012) Effect of five y ears of imatinib on cure for patients with advanced 
GIST: Updated survival results from the prospective randomized phase III BFR14 trial. J Clin 
Oncol 30, 2012 (suppl; abstr [ZIP_CODE]).
Blanke CD, Demetri GD, von Mehren M, et al (2008a) Long -term results from a randomized 
Phase II trial of standard -versus higher -dose imatinib mesy late for patients with unresectable 
or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26, 620 -625.
Blanke CD, Rankin C, Demetri GD, et al (2008b) Phase III randomized, intergroup trial 
assessing imatinib mes ylate at two dose levels in patients with unresectable or metastatic 
gastrointestinal stromal tumors expressing the kit receptor ty rosine kinase: S0033. J Clin 
Oncol 26, 626-632.
Corless C, Heinrich M (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. 
Annu Rev Pathol; 3:557 -86.
Deininger M, O'Brien SG, François Guilhot F, et al (2009) International Randomized Study  of 
Interferon Vs STI571 (I RIS) 8-Year Follow up: Sustained Survival and Low Risk for 
Progression or Events in Patients with Newly  Diagnosed Chronic My eloid Leukemia in 
Chronic Phase (CML -CP) Treated with Imatinib. Poster Abstract 1126: 51st ASH Annual 
Meeting; Dec 5 -8, New Orleans, LA.
DeMatt eo RP, Lewis JJ, Leung D, et al (2000) Two hundred gastrointestinal stromal tumors: 
recurrence patterns and prognostic factors for survival. Ann Surg; 231:51 –8.
Demetri G, von Mehren M, Antonescu CR, et al (2010) NCCN Task Force report: update on 
the manag ement of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw; 8: 
Suppl 2:S1 -
41.
Demetri GD, von Mehren M, Blanke CD, et al (2006) Efficacy  and safet y of sunitinib in 
patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized 
controlled trial. Lancet 368, 13291338.
Dileo P, Bauer S, Van den Abbeele A, et al (2006) Results with AMN107, a novel kinase 
inhibitor, in gastrointestinal stromal tumor (GI ST):Preclinical rationale and earl y results in a 
patient (P t) with imatinib (IM) -resistant GIST. 2006 Gastrointestinal Cancer Sy mposium. 
Abstr n. 53.
Frazer R, Irvine AE, McMullin MF (2007) Chronic My eloid Leukaemia in The 21st Century . 
Ulster Med J 76(1):8-17.
Heisterkamp N, Stephenson JR, Groffen J, et al (1983) Localization of the c -ab1 oncogene 
adjacent to a translocation break point in chronic my elocy tic leukaemia. Nature 
306(5940):239 -
42.
Kantarjian H, Shah NP, Hochhaus A, et al (2010) Dasatinib versus imatinib in newly  
diagnosed chronic -phase chronic m yeloid leukemia. N Engl J Med 362(24):2260 -70.

[COMPANY_001] Confidential Page 73
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human 
leukocy tes. J Natl Cancer I nst 25:85-109.
Prenen H, Guetens G, de Boeck G, et al (2006) Cellular uptake of the t yrosine kinase 
inhibito rs imatinib and AMN107 in Gastrointestinal stromal tumor cell lines. Pharmacology. 
77(1):11-16.
Rowley  JD (1973) Letter: A new consistent chromosomal abnormality  in chronic 
myelogenous leukaemia identified by  [CONTACT_5387]. Na ture 
243(5405):290 -3.
Saglio G, Kim DW, I ssaragrisil S, et al (2010) Nilotinib versus imatinib for newly  diagnosed 
chronic m yeloid leukemia. N Engl J Med 362(24):2251 -9.
Verweij J, et al (2004) Progression- free survival in Gastrointestinal Stromal tumours with 
High -dose Imatinib: Randomised Trial. Lancet 364, 1127 -1134.
Weisberg E, Manley  P, Mestan J, et al (2006) AMN107 (nilotinib): a novel and selective 
inhibitor of BCR -ABL. Br J Cancer 94(12):1765 -9.

[COMPANY_001] Confidential Page 74
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
14 Appendices
14.1 Appendix I: Guidance on concomitant medicat ions with CYP3A  
and QTc prolongation potential interactions
A list of drugs that are inducers and inhibitors and substrates of CYP3A4 is provided below.
Patients should be instructed not to take grapefruit, star fruit, pomegranate , St John’s Wort or 
Seville (sour) orange juice while recei ving study  treatment throughout the study  due to 
potential CYP3A4 induction or inhibition.
As the information listed below may  not be all inclusive, a list of CYP3A4 inhibitors ,inducers 
and substrat es may be found at http://medicine.iupui.edu/flockhart.
Table 14-[ADDRESS_4918]. John’s wort ( Hypericum perforatum )4
Moderate 
inducers of 
CYP3A42bosentan, dabrafenib, efavirenz, etravirine, genistein5, lersivirine , lopi[INVESTIGATOR_054], moda finil, nafcillin,
semagacestat6, talviraline6, telotristat, thioridazine, tipranavir/ritonavir
Weak inducers 
of CYP3A43amprenavir, aprepi[INVESTIGATOR_053], armodafinil, artesunate/mefloquine, bexarotene, boceprevir, 
brivacetam, clobazam, danshen ( Salvia miltiorrhiz a)4, dexamethasone, echinacea ( Echinacea 
purpurea )1, elvitegravir-cobicistat -emtricitabine -tenofovir (Stribild), eslicarbazepi[INVESTIGATOR_050], ginkgo 
(Ginkgo biloba )4, ginseng4, glycyrrhizin5, isavuconazole, lesinurad, methylprednisolone, 
nevirapi[INVESTIGATOR_050], ombitasvir/paritapre vir/dasabuvir/ritonavir (Viekira Pak), oritavancin, 
oxcarbazepi[INVESTIGATOR_050], pi[INVESTIGATOR_051], pleconaril, prednisone, pretomanib, primidone, quercetin5, 
raltegravir, ritonavir, rufinamide, sarilumab, sirukumab, sorafenib, sulfinpyrazone, telaprevir, 
terbinafine, ticagr elor, ticlopi[INVESTIGATOR_5325], topi[INVESTIGATOR_052], troglitazone6, vemurafenib, vicriviroc/ritonavir, 
vinblastine, yin zhi huang4
1A strong inducer for a specific CYP is defined as an inducer that decreases the AUC of a sensitive substrate for 
that CYP by [CONTACT_5388] 80%.
2A moderate inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that 
CYP by 50 -80%.
3A weak inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that CYP 
by 20 -50%.
[ADDRESS_4919] was based on information from the FDA’s “Guidance for Industry, Drug Interaction 
Studies”, from the Indiana Universit y School of Medicine’s “Clinicall y Relevant” Table, from 
the University of Washington’s Drug Interaction Database. This list may  not be comprehensive 
and may be updated periodically . Refer to [COMPANY_001] Oncology  Clinical Pharmacology  Internal 
Memorandum, Drug -drug interactions (DDI) Database (last updated January  2018) for update 
or more details.

[COMPANY_001] Confidential Page 75
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Table 14-[ADDRESS_4920] of medication metabolized by  [CONTACT_097]3 A4, strong, moderate and weak 
inhibitors of CYP3A 4 to be used with caution.
Category Drug Names
Strong inhibitors 
of CYP3A41atazanavir/ritonavir7, boceprevir, cobicistat,  conivaptan,  clarithromycin,
danoprevir/ritonavir7,  darunavir/ritonavir7,elvitegravir/ritonavir7,  grapefruit juice6,   
idelalisib, indinavir,  indinavir/ritonavir7,  itraconazole,  ketoconazole, lopi[INVESTIGATOR_5326] r/ritonavir7,   
mibefradil, nefazodone, nelfinavir,  ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak)7,  
posaconazole,  ritonavir,  saquinavir/ritonavir7,, saquinavir, telaprevir,  telithromycin, 
tipranavir/ritonavir7, troleandomycin, , voriconazol
Moderate 
inhibitors of 
CYP3A42aprepi[INVESTIGATOR_053], amprenavir,  asafoetida resin ( Ferula asafoetida )4,atazanavir, cimetidine, 
casopi[INVESTIGATOR_053], ciprofloxacin, crizotinib, cyclosporine, darunavir, diltiazem, dronedarone, 
erythromycin, faldaprevir, fluconazo le, grapefruit juice6, imatinib, isavuconazole, netupi[INVESTIGATOR_053], 
nilotinib, Schisandra sphenanthera (nan wu wei zi)4,tofisopam, verapamil
Weak inhibitors 
of CYP3A43almorexant, alprazolam, amiodarone, amlodipi[INVESTIGATOR_050], atorvastatin, azithromycin, berberine4, 
bicalutamide, blueberry juice8, brodalumab, chlorzoxazone, cilostazol, clotrimazole, 
cranberry juice8, daclatasvir, delavirdine, evacetrapib, everolimus, flibanserin, fluvoxamine, 
fosaprepi[INVESTIGATOR_053] (IV), fostamatinib, garden cress seeds ( Lepi[INVESTIGATOR_5327] )5, ginkgo (Ginkgo 
biloba )4, goldenseal (Hydrastis canadensis )4, grazoprevir, guan mai ning4, isoniazid, 
ivacaftor, lacidipi[INVESTIGATOR_050], linagliptin, lomitapi[INVESTIGATOR_5328], obeticholic acid, oral contraceptives, palbociclib, 
pazopanib, peppermint oil5, pi[INVESTIGATOR_5329]5, pomelo ( Citrus grandis )5, propi[INVESTIGATOR_5330], ranitidine, 
ranolazine, resveratrol4, roxithromycin, Seville orange juice5, simeprevir, sitaxentan, 
suvorexant, tabimorelin, tacrolimus, teriflunomide, ticagrelor, tolvaptan, tong xin luo4
1A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate 
for that CYP by [CONTACT_5388] [ADDRESS_4921] shown that it can be classified as a “strong CYP3A inhibitor” when a certain 
preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another 
preparation was used (e.g., low dose, single strength). 
7Combination ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A inhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database.
8The effect of certain fruit juices varies widely among brands and is concentration -, dose -, and preparation -
dependent.
This list is based on information from the FDA’s “Guidance for Industry , Drug Interaction 
Studies”, from the Indiana University  School of Medicine’s “Clinically  Relevant” Table and 
from the University  of Washington’s Drug Interaction Database. Please note that this is not an
exhaustive list. Please refer to footnotes. Refer to [COMPANY_001] Oncology  Clinical Pharmacology  
Internal Memorandum, Drug -drug interactions (DDI) Database (last updated January  2018) for 
update or more details.

[COMPANY_001] Confidential Page 76
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Table 14 -3 CYP3 A4 substrates: Narrow therapeutic index, sensitive, and others.
Category Drug Names
Narrow 
Therapeutic 
index substrates 
of CYP3A41alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, 
pi[INVESTIGATOR_3924], quinidine, sirolimus, tacrolimus, terfanadine, thioridazine
Sensitive 
substrates of 
CYP3A42alfentanil, alpha -dihydroergocryptine, almorexant , alisoporivir, aplaviroc, aprepi[INVESTIGATOR_053], 
atazanavir, atorvastatin, avanafil, bosutinib, brecanavir, brotizolam, budesonide, buspi[INVESTIGATOR_5331], 
capravirine, casopi[INVESTIGATOR_053], c obimetinib, conivaptan, danoprevir, darifenacin, darunavir, 
dasatinib, dronedarone, ebastine, eletriptan, elvitegravir, eplerenone, everolimus, 
felodipi[INVESTIGATOR_050], fluticasone, grazoprevir, ibrutinib, indinavir, isavuconazole, ivabradine, ivacaftor, 
levomethadyl ( LAAM), lomitapi[INVESTIGATOR_5328], lopi[INVESTIGATOR_054], lovastatin, lumefantrine, lurasidone, maraviroc, 
midazolam, midostaurin, naloxegol, neratinib, nisoldipi[INVESTIGATOR_050], paritaprevir, perospi[INVESTIGATOR_5331], 
quetiapi[INVESTIGATOR_050], ridaforolimus, saquinavir, sildenafil, simeprevir, simvastatin, tacrolimus, 
terfenadine, ticagrelor, tilidine, tipranavir, tolvaptan, triazolam, ulipristal, vardenafil, 
venetoclax, vicriviroc, voclosporin
Other 
Substrates of 
CYP3A43alprazolam, ambrisentan, amlodipi[INVESTIGATOR_050], antipyrine, aripi[INVESTIGATOR_4253], artemether, avosentan, 
boceprevir, bos entan, buprenorphine, Cannabis sativa4, carbamazepi[INVESTIGATOR_050], dexloxiglumide, 
dextromethorphan, diazepam, docetaxel, enzalutamide, gemigliptin, halofantrine, 
imipramine, lansoprazole, lidocaine, linagliptin, loperamide, loratadine, losartan, lurasidone, 
macitentan, methadone, mirodenafil, montelukast, morphine, nelfinavir, netupi[INVESTIGATOR_053], 
nevirapi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nilotinib ,nitrendipi[INVESTIGATOR_050], omeprazole, ospemifene, oxycodone, 
paclitaxel, pazopanib, pi[INVESTIGATOR_051], quinine, ranolazine, repaglinide, rifabutin, ritonav ir, 
roflumilast, saxagliptin, selegiline, sertraline, sibutramine, sotrastaurin, telaprevir, 
theophylline, tirilazad, tolterodine, udenafil, vincristine, voriconazole
[ADDRESS_4922] <2 -fold difference in the minimum toxic concentrations and minimum effective concentrations in the 
blood (thus saf e and effective use requires careful dosage titration and patient monitoring).
2Sensitive substrates are drugs that demonstrate an increase in AUC of ≥5-fold with strong index inhibitors of 
a given metabolic pathway in clinical DDI studies.
3Other substr ates are drugs that demonstrate an increase in AUC of ≥2 to <[ADDRESS_4923] in clinical DDI studies.
4Tetrahydrocannabinol ( 9THC) and cannabidiol (CBD) are major constituents. 9THC is primarily metabolized 
by [CONTACT_097]2C9 to an active metabolite 11 -hydroxy -9-THC (11 -OH-THC). CBD is extensively metabolized by 
[CONTACT_097]2C19 and CYP3A4 to eight monohydroxylated metabolites. The effects of multiple daily doses of rifampi[INVESTIGATOR_2513] 
600 mg for 10 days, ketoconazole 400 mg for 6 days and omeprazole 40 mg for 6 days on the PK of 9THC, 
11-OH -THC and CBD after a single dose (4 sprays) of an oromucosal spray were determined in a randomized, 
crossover, parallel study in three groups of 12 male subjects. Ketoconazole increased the Cmax and AUC0 -24 
of 9THC by 1.2 -and 1.8 -fold, respectively, increased the Cmax and AUC0-24 of 11 -OH-THC by 3.0 -and 2.6 -
fold, respectively, and increased the Cmax and AUC0 -24 of CBD by 2 - and 2-fold, respectively. Rifampi[INVESTIGATOR_5332]24 of 9THC by 40 and 20%, respectively, decreased the Cmax and AUC0 -24 
of 11 -OH-THC by 85 and 87%, respectively, and decreased the Cmax and AUC24 of CBD by 50 and 60%, 
respectively. There were no effects of omeprazole on the plasma concentrations of all three cannabis 
constituents.
This list of CYP substrates was compi[INVESTIGATOR_5333]’s 
“Clinically  Relevant” Table; from the FDA’s “Guidance for Industry , Drug Interaction Studies” 
and from the University of Washington’s Drug Interaction Database. This list may not be 
comprehensive and may be updated periodically . Refer to [COMPANY_001] Oncology  Clinical 
Pharmacology  Internal Memorandum, Drug -drug interactions (DDI) Database (last updated 
January  2018) for update or more details.

[COMPANY_001] Confidential Page 77
Amended Protocol Version 0 5 (Clean ) Protocol N o. CAMN107A2409
Guidance on QT prolongation agents
A list of drugs associated with QT prolongation and/or Torsades de Pointes is available online
at https://crediblemeds.org/  
